ImmunityBio (IBRX) 10-Q 14 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 12, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Trading Symbol	IBRX
Entity Registrant Name	IMMUNITYBIO, INC.
Entity Central Index Key	0001326110
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding		383,905,840
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity File Number	001-37507
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	43-1979754
Entity Address, Address Line One	3530 John Hopkins Court
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	633-0300
Document Quarterly Report	true
Document Transition Report	false

Condensed Combined Consolidated

Condensed Combined Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 44,679	$ 34,915
Marketable securities	38,594	61,146
Due from related parties	2,057	2,003
Prepaid expenses and other current assets (including amounts with related parties)	14,242	13,649
Total current assets	99,572	111,713
Marketable securities, noncurrent	1,000	950
Property, plant and equipment, net	80,875	72,541
Non-marketable equity investment (Note 4)	0	7,849
Intangible asset, net	1,438	1,463
Convertible note receivable	6,191	6,129
Operating lease right-of-use assets, net (including amounts with related parties)	18,447	18,138
Other assets (including amounts with related parties)	1,905	2,598
Total assets	209,428	221,381
Current liabilities:
Accounts payable	20,097	11,510
Accrued expenses and other liabilities	36,793	36,771
Due to related parties	17,817	14,838
Operating lease liabilities (including amounts with related parties)	5,156	5,015
Total current liabilities	79,863	68,134
Related-party notes payable	297,286	254,353
Operating lease liabilities, less current portion (including amounts with related parties)	16,554	16,179
Deferred income tax liability	170	170
Other liabilities	891	1,035
Total liabilities	394,764	339,871
Commitments and contingencies (Note 8)	0	0
Stockholders’ deficit:
Common stock, $0.0001 par value; 500,000,000 shares authorized; 383,067,321 and 382,243,142 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively; excluding treasury stock, 163,800 shares outstanding as of March 31, 2021 and December 31, 2020, respectively	38	38
Additional paid-in capital	1,508,958	1,495,163
Accumulated deficit	(1,694,745)	(1,615,131)
Accumulated other comprehensive (loss) income	(38)	122
Total ImmunityBio stockholders’ deficit	(185,787)	(119,808)
Noncontrolling interests	451	1,318
Total stockholders’ deficit	(185,336)	(118,490)
Total liabilities and stockholders’ deficit	$ 209,428	$ 221,381

Condensed Combined Consolidat_2

Condensed Combined Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	383,067,321	382,243,142
Common stock, shares outstanding	383,067,321	382,243,142
Treasury Stock, Shares	163,800	163,800

Condensed Combined Consolidat_3

Condensed Combined Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenue	$ 139	$ 165
Operating expenses:
Research and development (including amounts with related parties)	41,128	27,374
Selling, general and administrative (including amounts with related parties)	45,275	9,493
Total operating expenses	86,403	36,867
Loss from operations	(86,264)	(36,702)
Other income (expense):
Interest and investment income, net	8,944	78
Interest expense (including amounts with related parties)	(3,168)	(1,889)
Other income, net (including amounts with related parties)	13	1,104
Total other income (expense)	5,789	(707)
Loss before income taxes and noncontrolling interests	(80,475)	(37,409)
Income tax expense	(6)	(18)
Net loss	(80,481)	(37,427)
Net loss attributable to noncontrolling interests, net of tax	(867)	(389)
Net loss attributable to ImmunityBio common stockholders	$ (79,614)	$ (37,038)
Net loss per ImmunityBio common share – basic and diluted	$ (0.21)	$ (0.10)
Weighted-average number of common shares used in computing net loss per share – basic and diluted	382,741,464	371,989,232

Condensed Combined Consolidat_4

Condensed Combined Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (80,481)	$ (37,427)
Other comprehensive (loss) income, net of income taxes:
Net unrealized losses on available-for-sale securities	(1)	(24)
Foreign currency translation adjustments	(162)	70
Reclassification of net realized losses on available-for-sale securities included in net loss	3	1
Total other comprehensive (loss) income	(160)	47
Comprehensive loss	(80,641)	(37,380)
Comprehensive loss attributable to noncontrolling interests	(867)	(389)
Comprehensive loss attributable ImmunityBio common stockholders	$ (79,774)	$ (36,991)

Condensed Combined Consolidat_5

Condensed Combined Consolidated Statements of (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income	Total ImmunityBio Stockholders’ Equity (Deficit)	Noncontrolling Interests
Beginning Balance at Dec. 31, 2019	$ 16,326	$ 37	$ 1,406,002	$ (1,393,280)	$ (87)	$ 12,672	$ 3,654
Beginning Balance, Shares at Dec. 31, 2019		371,976,995
Stock-based compensation expense	480	$ 0	480	0	0	480	0
Vesting of restricted stock units (RSUs)	0	$ 0	0	0	0	0	0
Vesting of restricted stock units (RSUs), Shares		63,750
Net share settlement for RSUs vesting	(123)	$ 0	(123)	0	0	(123)	0
Net share settlement for RSUs vesting, Shares		(25,722)
Other comprehensive income (loss)	47	$ 0	0	0	47	47	0
Net loss	(37,427)	0	0	(37,038)	0	(37,038)	(389)
Ending Balance at Mar. 31, 2020	(20,697)	$ 37	1,406,359	(1,430,318)	(40)	(23,962)	3,265
Ending Balance, Shares at Mar. 31, 2020		372,015,023
Beginning Balance at Dec. 31, 2020	$ (118,490)	$ 38	1,495,163	(1,615,131)	122	(119,808)	1,318
Beginning Balance, Shares at Dec. 31, 2020	382,243,142	382,243,142
Stock-based compensation expense	$ 15,298	$ 0	15,298	0	0	15,298	0
Exercise of stock options	1,121	$ 0	1,121	0	0	1,121	0
Exercise of stock options, Shares		690,465
Vesting of restricted stock units (RSUs)	0	$ 0	0	0	0	0	0
Vesting of restricted stock units (RSUs), Shares		235,725
Net share settlement for RSUs vesting	(2,624)	$ 0	(2,624)	0	0	(2,624)	0
Net share settlement for RSUs vesting, Shares		(102,011)
Other comprehensive income (loss)	(160)	$ 0	0	0	(160)	(160)	0
Net loss	(80,481)	0	0	(79,614)	0	(79,614)	(867)
Ending Balance at Mar. 31, 2021	$ (185,336)	$ 38	$ 1,508,958	$ (1,694,745)	$ (38)	$ (185,787)	$ 451
Ending Balance, Shares at Mar. 31, 2021	383,067,321	383,067,321

Condensed Combined Consolidat_6

Condensed Combined Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating activities:
Net loss	$ (80,481)	$ (37,427)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	15,298	480
Unrealized (gains) losses on equity securities	(8,834)	202
Non-cash interest items, net (including amounts with related parties)	3,435	1,965
Depreciation and amortization	2,972	3,461
Non-cash lease expense related to operating lease right-of-use assets	1,555	1,177
Amortization of net premiums and discounts on marketable debt securities	225	45
Deferred tax	0	(1,067)
Other	(125)	4
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(934)	(4,020)
Other assets	693	322
Accounts payable	6,497	(1,724)
Accrued expenses and other liabilities	(1,893)	8,228
Related parties	2,597	(2,411)
Operating lease liabilities	(1,474)	(342)
Net cash used in operating activities	(60,469)	(31,107)
Investing activities:
Purchases of property, plant and equipment	(7,083)	(315)
Purchases of marketable debt securities, available-for-sale	(91)	(10,300)
Maturities of marketable debt securities	31,925	23,109
Proceeds from sales of marketable debt securities	7,094	1,500
Net cash provided by investing activities	31,845	13,994
Financing activities:
Proceeds from issuance of related-party promissory notes	40,000	0
Proceeds from exercises of stock options	1,121	0
Net share settlement for RSUs vesting	(2,624)	(123)
Net cash provided by (used in) financing activities	38,497	(123)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(109)	89
Net change in cash, cash equivalents, and restricted cash	9,764	(17,147)
Cash, cash equivalents, and restricted cash, beginning of period	35,094	75,980
Cash, cash equivalents, and restricted cash, end of period	44,858	58,833
Reconciliation of cash, cash equivalents, and restricted cash, end of period:
Cash and cash equivalents	44,679	58,654
Restricted cash (Note 3)	179	179
Cash, cash equivalents, and restricted cash, end of period	44,858	58,833
Supplemental disclosure of cash flow information:
Interest	12	7
Income taxes	2	0
Supplemental disclosure of non-cash activities:
Property and equipment purchases included in accounts payable, accrued expenses, and due to related parties	(4,267)	(367)
Right-of-use assets obtained in exchange for operating lease liabilities	1,388	0
Unrealized gains on marketable debt securities	$ 14	$ 23

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1. Description of Business Organization We were We established ImmunityBio to advance the next-generation immunotherapies and to address unmet needs within oncology and infectious disease. Our platform is designed to overcome limitations of the current standards of T cell-based immunotherapies, including checkpoint inhibitors and CAR-T cells and is based on our four key modalities: (1) activating natural killer, or NK, and T cells using antibody cytokine fusion proteins, (2) activating tumoricidal macrophages using low-dose synthetic immunomodulators, (3) generating memory T cells using vaccine candidates developed with our second-generation adenovirus, or hAd5, technology, and (4) off-the-shelf natural killer cells from the NK‑92 cell line and memory-like cytokine-enhanced natural killer cells (m‑ceNK) from allogenic and autologous donors. We own a broad, clinical-stage immunotherapy pipeline, including an antibody cytokine fusion protein (an IL‑15 superagonist (N‑803) known as Anktiva), an albumin-associated anthracycline synthetic immunomodulator (aldoxorubicin), second-generation adenovirus (hAd5) and yeast vaccine technologies (targeting tumor-associated antigens and neoepitopes), off-the-shelf genetically engineered natural killer cell lines inducing cancer and virally infected cell death through a variety of concurrent mechanisms (including innate killing, antibody-mediated killing, and CAR-directed killing), patient specific NK cell product for cancer that is an autologous Memory cytokine enhanced Natural Killer cells, macrophage polarizing peptides, and bi-specific fusion proteins targeting CD20, PD‑L1, TGF‑ b and IL‑12. Our immunotherapy clinical pipeline consists of over 40 clinical trials in Phase 1, 2, or 3 development across 19 indications in solid and liquid cancers and infectious diseases. We have an expansive clinical-stage pipeline and intellectual property portfolio with 17 first-in-human assets in 25 Phase II to III clinical trials. In December 2019, the , or FDA, granted Breakthrough Therapy designation to Anktiva for bacillus Calmette-Guérin, or BCG, unresponsive carcinoma in situ non-muscle invasive bladder cancer. Other indications currently with registration-potential studies include BCG unresponsive papillary bladder cancer, first- and second-line lung cancer, and metastatic pancreatic cancer. The Merger On December 21, 2020, we and NantCell, Inc. (formerly known as ImmunityBio, Inc., a private company) (“NantCell”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which we and NantCell agreed to combine our businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell (the “Merger”), with NantCell surviving the Merger as a wholly-owned subsidiary of the company. On March 9, 2021, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of NantCell common stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive 0.8190 (the “Exchange Ratio”) newly At the Effective Time, each share of the company’s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, warrant or restricted stock unit to purchase NantCell common stock was converted using the Exchange Ratio into an option, warrant or restricted stock unit, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock. Immediately following the Effective Time, the former stockholders of NantCell held approximately 71.5% of the outstanding shares of Company Common Stock and the stockholders of the company as of immediately prior to the Merger held approximately 28.5% of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr. Patrick Soon-Shiong, our Executive Chairman, and his affiliates beneficially own, in the aggregate, approximately 81.8% of the outstanding shares of Company Common Stock. Following the consummation of the Merger, shares of the company’s common stock are now listed on the Nasdaq Global Select Market under the symbol “IBRX.” We incurred costs totaling $23.2 million in connection with the Merger, consisting of financial advisory, legal and other professional fees, of which $12.9 million was recorded during the three months ended March 31, 2021. Merger-related costs are reported in selling, general and administrative expense , on the condensed combined consolidated statements of operations. Accounting Treatment of the Merger The Merger represents a business combination pursuant to Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 805-50, Mergers The following table provides the impact of the change in reporting entity on our unaudited condensed combined consolidated statements of operations for the three months ended March 31, 2021 and 2020 (in thousands): Three Months Ended March 31, 2021 NantCell NantKwest Intercompany Eliminations ImmunityBio, Inc. Revenue $ 183 $ — $ (44 ) $ 139 Operating expenses: Research and development (including amounts with related parties) 21,509 19,725 (106 ) 41,128 Selling, general and administrative (including amounts with related parties) 24,382 20,903 (10 ) 45,275 Loss from operations (45,708 ) (40,628 ) 72 (86,264 ) Other (expense) income, net (including amounts with related parties) (848 ) 6,637 — 5,789 Income tax expense — (6 ) — (6 ) Net loss $ (46,556 ) $ (33,997 ) $ 72 $ (80,481 ) Three Months Ended March 31, 2020 NantCell NantKwest Intercompany Eliminations ImmunityBio, Inc. Revenue $ 168 $ 21 $ (24 ) $ 165 Operating expenses: Research and development (including amounts with related parties) 14,252 13,234 (112 ) 27,374 Selling, general and administrative (including amounts with related parties) 4,120 5,373 — 9,493 Loss from operations (18,204 ) (18,586 ) 88 (36,702 ) Other (expense) income, net (including amounts with related parties) (910 ) 203 — (707 ) Income tax expense (18 ) — — (18 ) Net loss $ (19,132 ) $ (18,383 ) $ 88 $ (37,427 )

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies There have been no material changes to our significant accounting policies from those described in the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) filed as Exhibit 99.2 to our Current Report on Form 8‑K/A filed with the Securities and Exchange Commission, or SEC, on April 22, 2021. Basis of Presentation The accompanying unaudited condensed combined consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, and pursuant to the rules and regulations of the SEC. The unaudited condensed combined consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed combined consolidated financial statements do not include all information and notes required by U.S. GAAP for annual reports. As of March 31, 2021, the company had an accumulated deficit of $1.7 billion. We also had negative cash flows from operations of $60.5 million for the three months ended March 31, 2021. The company will likely need additional capital to further fund the development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products. The condensed combined consolidated financial statements are derived from the company’s and NantCell’s respective historical consolidated financial statements for each period presented. Since the entities have been under common control for all periods presented, the condensed combined consolidated financial statements assume that the Merger took place at the beginning of the earliest period for which the condensed combined consolidated financial statements are presented. Accordingly, these financial statements should be read in conjunction with the audited combined consolidated financial statements and notes thereto for the fiscal year ended December 31, 2020 included in the Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) filed as Exhibit 99.2 to our Current Report on Form 8‑K/A filed with the SEC on April 22, 2021. Interim operating results are not necessarily indicative of operating results for the full year. The condensed combined consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $500.0 million of our common stock that may be issued and sold under an “at-the-market” sales agreement with Jefferies LLC, or the ATM, and our potential ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12 months following the issuance date of the financial statements based primarily upon our Executive Chairman’s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned. Principles of Consolidation The accompanying unaudited condensed combined consolidated financial statements include the accounts of the company and its subsidiaries. All intercompany amounts have been eliminated. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest in our condensed combined consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. We apply the variable interest model under ASC Topic 810, Consolidation For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model. Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20% to 50% interest in the voting securities of the entity. All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in interest and investment income, net Fair Value Measurement Investments—Equity Securities Prior to March 31, 2021, we owned non-marketable equity securities that were accounted for using the measurement alternative under ASC 321 because the preferred stock held by us was not considered in-substance common stock and such preferred stock did not have a readily determinable fair value. All investments are reviewed for possible impairment on a regular basis. If an investment’s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include: the investees’ earnings performance and clinical trial performance, change in the investees’ industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee’s ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include: the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours. Use of Estimates The preparation of condensed combined consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed combined consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates. Risks and Uncertainties In March 2020, the World Health Organization declared the novel strain of coronavirus disease (SARS‑CoV‑2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected. Contingencies We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable. Our cash and cash equivalents are held by one major financial institution in the U.S., one in South Korea and one in Italy. Product candidates developed by us will require approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us. Stock-Based Compensation We account for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation Basic and Diluted Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of p otentially dilutive securities: As of March 31, 2021 2020 (Unaudited) Outstanding stock options 4,978,314 6,080,483 Outstanding RSUs 7,636,132 1,102,528 Outstanding related-party warrants 1,638,000 1,638,000 Total 14,252,446 8,821,011 Amounts in the table above reflect the common stock equivalents of the noted instruments, including awards issued under the NantKwest 2015 Equity Incentive Plan (the “2015 Plan”), the NantKwest 2014 Equity Incentive Plan (the “2014 Plan”), and awards issued under the NantCell, Inc. 2015 Stock Incentive Plan (the “NC 2015 Plan”) that, in the case of March 31, 2021, were outstanding immediately prior to the Effective Time of the Merger and in the case of March 31, 2020 have been adjusted to include the combined NC 2015 Plan and NantCell warrants then outstanding (in both cases adjusted using the Merger Exchange Ratio of 0.8190 Note 11 , Stock-Based Compensation Recent Accounting Pronouncements Application of New or Revised Accounting Standards – Not Yet Adopted In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016‑13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three months ended March 31, 2021 did not, or are not expected to, have a material effect on our consolidated financial statements.

Financial Statement Details

Financial Statement Details	3 Months Ended
	Mar. 31, 2021
Financial Statement Details [Abstract]
Financial Statement Details	3. Financial Statement Details Prepaid expenses and other current assets As of March 31, 2021 and December 31, 2020, prepaid expenses and other current assets consist of the following (in thousands): March 31, 2021 December 31, 2020 (Unaudited) Prepaid preclinical and clinical trial services – with related party (Note 9) $ 4,648 $ 4,626 Insurance claim receivable 2,932 2,518 Prepaid services 1,435 1,294 Prepaid license fees 1,329 801 Prepaid insurance 1,230 1,365 Insurance premium financing asset 571 1,421 Prepaid rent 569 589 Equipment deposits 375 66 Tenant improvement receivables – with related party (Note 9) 313 — Prepaid equipment maintenance 239 243 Interest receivable – 132 473 Prepaid supplies – with related party (Note 9) 131 143 Other 338 110 Prepaid expenses and other current assets $ 14,242 $ 13,649 We have reflected our right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. Our insurance claims receivable as of March 31, 2021 and December 31, 2020 are the result of the recovery of legal costs, which had been previously charged in prior periods to s elling, general and administrative expense, on the condensed combined consolidated statements of operations. Property, plant and equipment, net As of March 31, 2021 and December 31, 2020, property, plant and equipment, net, consist of the following (in thousands): March 31, 2021 December 31, 2020 (Unaudited) Leasehold improvements $ 52,200 $ 52,251 Equipment 38,556 34,738 Buildings 22,690 22,690 Construction in progress 8,308 1,333 Software 2,659 2,376 Furniture & fixtures 1,007 1,015 Gross property, plant and equipment 125,420 114,403 Less: Accumulated depreciation and amortization 44,545 41,862 Property, plant and equipment, net $ 80,875 $ 72,541 Construction in progress at March 31, 2021 is related primarily to expansion of our hAd5 pharmaceutical development and manufacturing facilities, including construction of a new filling suite at our leased facilities in El Segundo, California . Depreciation and amortization expense related to property, plant and equipment totaled $3.0 million and $3.5 million for the three months ended March 31, 2021 and 2020, respectively. Other assets As of March 31, 2021 and December 31, 2020, other assets consist of the following (in thousands): March 31, 2021 December 31, 2020 (Unaudited) VAT receivable $ 810 $ 864 Security deposits 319 634 Prepaid software license fees 227 455 Restricted cash 179 179 Due from related party 54 51 Prepaid preclinical and clinical trial services – with related party (Note 9) — 92 Other 316 323 Other assets $ 1,905 $ 2,598 Restricted cash is comprised of a certificate of deposit that serves as collateral for a letter of credit required by our landlord as a security deposit related to our facility in San Diego, California. Accrued expenses and other liabilities As of March 31, 2021 and December 31, 2020, accrued expenses and other liabilities consist of the following (in thousands): March 31, 2021 December 31, 2020 (Unaudited) Accrued bonus $ 6,947 $ 5,288 Accrued dissenting shares (Note 8) 6,854 6,769 Accrued professional and service fees 6,728 7,668 Accrued preclinical and clinical trial costs 4,656 4,339 Accrued compensation 4,349 3,891 Accrued research and development costs 2,103 4,002 Accrued construction costs 1,931 — Accrued contingent consideration payable 822 856 Accrued laboratory equipment and supplies 681 641 Financing obligation – 571 1,421 Deferred revenue 263 270 Accrued franchise, sales, use and property taxes 113 103 Accrued capital expenditures 16 337 Other 759 1,186 Accrued expenses and other liabilities $ 36,793 $ 36,771 Interest and investment income, net Interest and investment income, net consists of the following (in thousands): Three Months Ended March 31, 2021 2020 (Unaudited) Unrealized gains (losses) from equity securities $ 8,833 $ (198 ) Interest income 339 322 Investment amortization expense, net (225 ) (45 ) Net realized losses on investments (3 ) (1 ) Interest and investment income, net $ 8,944 $ 78 Interest income includes interest from marketable securities, convertible notes receivable, other assets, and interest from bank deposits. We did not recognize an impairment loss on any investments during the three months ended March 31, 2021 and 2020.

Equity Investment in Viracta Th

Equity Investment in Viracta Therapeutics	3 Months Ended
	Mar. 31, 2021
Viracta Therapeutics, Inc.
Investment	4. Equity Investment in Viracta Therapeutics In March 2017, we participated in a Series B convertible preferred stock financing and invested $8.5 million in Viracta Therapeutics, Inc., or Viracta, a clinical stage drug development company, which was initially recorded at cost. In May 2017, we executed an exclusive worldwide license with Viracta to develop and commercialize Viracta’s proprietary histone deacetylase inhibitor drug candidate for use in combination with natural killer cell therapy and possibly additional therapies. In June 2018, Viracta executed a 2018 Note and Warrant Purchase Agreement with existing and new investors, including us. The initial closing under the Purchase Agreement occurred in June 2018, at which point we purchased a convertible note for $0.4 million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta’s common stock. In September 2018, a milestone closing under the Purchase Agreement occurred, at which point we purchased an additional convertible note for $0.4 million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta’s common stock. Effective January 31, 2019, the notes, together with accrued interest then outstanding, were converted to Series B preferred stock resulting in an increase to our investment in Viracta’s Series B convertible preferred stock of $0.8 million. In May 2019, we exercised warrants to acquire 253,120 shares of Viracta common stock. Based on the level of equity investment at risk, Viracta was not a VIE and therefore was not consolidated under the VIE model. In addition, we did not hold a controlling financial interest in Viracta, and therefore we did not consolidate Viracta under the voting interest model. As the preferred stock was not considered in-substance common stock, the investment was not within the scope of accounting for the investment under the equity method. As the preferred stock did not have a readily determinable fair value and did not qualify for the practical expedient to estimate fair value in accordance with ASC 820, we had elected to apply the measurement alternative under ASC 321, pursuant to which we measured our investment in Viracta at cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer. As of December 31, 2020, our fair value assessment indicated that the offering of Viracta’s Series E preferred stock in November 2020, at a lower offering price per share than the per share carrying amount of our investment in Viracta, was a directional indicator representing an observable price change in an orderly transaction for a similar investment. On December 31, 2020, we reduced the carrying value by $1.4 million due to the observable price change, which was included in interest and investment income, net non-marketable equity investment, On February 24, 2021, Sunesis Pharmaceuticals, Inc., a public company, completed a business combination with Viracta. In connection with this business combination, our preferred stock investment in Viracta was converted into 1,562,604 shares of Viracta common stock effective February 25, 2021. As of March 31, 2021, the carrying value of our investment in Viracta, which is reflected in marketable securities

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2021
Marketable Debt and Equity Securities
Investment	5. Financial Instruments Investments in Marketable Debt Securities As of March 31, 2021, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in thousands): March 31, 2021 (Unaudited) Weighted- Average Remaining Contractual Life (in years) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Current: Corporate debt securities 0.2 $ 15,541 $ 1 $ (4 ) $ 15,538 Mutual funds 35 2 — 37 Current portion 15,576 3 (4 ) 15,575 Noncurrent: Foreign bonds 5.1 861 139 — 1,000 Noncurrent portion 861 139 — 1,000 Total $ 16,437 $ 142 $ (4 ) $ 16,575 As of December 31, 2020, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in thousands): December 31, Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Current: Corporate debt securities $ 54,789 $ 2 $ (19 ) $ 54,772 Mutual funds 35 2 — 37 Current portion 54,824 4 (19 ) 54,809 Noncurrent: Foreign bonds 861 89 — 950 Noncurrent portion 861 89 — 950 Total $ 55,685 $ 93 $ (19 ) $ 55,759 Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12 months and for more than 12 months as of March 31, 2021 and December 31, 2020 were as follows (in thousands): March 31, 2021 (Unaudited) Less than 12 months More than 12 months Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Corporate debt securities $ 13,535 $ (4 ) $ — $ — Total $ 13,535 $ (4 ) $ — $ — December 31, 2020 Less than 12 months More than 12 months Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Corporate debt securities $ 42,762 $ (19 ) $ — $ — Total $ 42,762 $ (19 ) $ — $ — As of March 31, 2021, a total of 14 of the securities were in unrealized loss positions. We evaluated our securities for other-than-temporary impairment and concluded that the decline in value was primarily caused by current economic and market conditions. We do not intend to sell the investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost bases. Therefore, we did not recognize any other-than-temporary impairment losses during the three months ended March 31, 2021. Realized gains and losses on sales of available-for-sale debt securities during the three months ended March 31, 2021 and 2020 were not material. Marketable Equity Securities We held investments in marketable equity securities with readily determinable fair values of $23.0 million and $6.3 million as of March 31, 2021 and December 31, 2020, respectively. Unrealized gains recognized on equity securities with readily determinable fair values totaled $8.8 million for the three months ended March 31, 2021, while unrealized losses recognized on equity securities with readily determinable fair values totaled $0.2 million for the three months ended March 31, 2020. There were no realized gains or losses on sales of equity securities for the three months ended March 31, 2021 and 2020.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: • Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of bank deposits, money market funds, and marketable equity securities. • Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level 2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities. • Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement. We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations. Recurring Valuations Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March 31, 2021 and December 31, 2020 (in thousands): Fair Value Measurements as of March 31, 2021 (Unaudited) Total Level 1 Level 2 Level 3 Assets: Current: Cash and cash equivalents $ 44,679 $ 44,679 $ — $ — Equity securities (1) 23,019 23,019 — — Corporate debt securities 15,538 — 15,538 — Mutual funds 37 37 — — Noncurrent: Foreign bonds 1,000 1,000 — — Total assets measured at fair value $ 84,273 $ 68,735 $ 15,538 $ — Liabilities: Contingent consideration obligations (2) $ (844 ) $ — $ — $ (844 ) Fair Value Measurements as of December 31, 2020 Total Level 1 Level 2 Level 3 Assets: Current: Cash and cash equivalents $ 34,915 $ 34,915 $ — $ — Corporate debt securities 54,772 — 54,772 — Equity securities 6,337 6,337 — — Mutual funds 37 37 — — Noncurrent: Foreign bonds 950 950 — — Total assets measured at fair value $ 97,011 $ 42,239 $ 54,772 $ — Liabilities: Contingent consideration obligations (2) $ (972 ) $ — $ — $ (972 ) (1) Our equity securities include our investment in Viracta totaling $14.5 million, which was previously accounted for by applying the measurement alternative under ASC 321. In February 2021, Viracta merged with Sunesis Pharmaceuticals, Inc., a public company. In connection with this transaction, our preferred stock investment in Viracta was converted into 1,562,604 shares of Viracta common stock effective February 25, 2021. See Note 4 , Equity Investment in Viracta Therapeutics , for additional information. (2) Contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level 3 measurement within the fair value hierarchy) and are reviewed periodically by management. See Note 8 , Commitments and Contingencies, for additional information. Changes in the carrying amount of contingent consideration obligations were as follows (in thousands): Three Months Ended March 31, 2021 2020 (Unaudited) Fair value, beginning of period $ (972 ) $ (1,725 ) Net change in fair value 128 (2 ) Fair value, end of period $ (844 ) $ (1,727 ) Non-recurring Valuations Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. There were no material non-financial assets and liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis during the three months ended March 31, 2021 and 2020.

Collaboration and License Agree

Collaboration and License Agreements	3 Months Ended
	Mar. 31, 2021
Research And Development [Abstract]
Collaboration and License Agreements	7. Collaboration and License Agreements National Cancer Institute In May 2015, Etubics Corporation, or Etubics, entered into a Cooperative Research and Development Agreement, or CRADA, with the U.S. Department of Health and Human Services as represented by the National Cancer Institute, or NCI, of the National Institutes of Health, or NIH, to collaborate on the preclinical and clinical development of an adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. In January 2016, we acquired all of the outstanding equity interests in Etubics and Etubics became a wholly-owned subsidiary. Effective January 2018, we assumed the CRADA and it was amended to cover a collaboration for the preclinical and clinical development of our proprietary yeast-based Tarmogens expressing tumor-associated antigens and proprietary adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. Pursuant to the CRADA, NIH provides scientific staff and other support necessary to conduct research and related activities as described in the CRADA. During the term of the CRADA, we are required to make annual payments of $0.6 million to the NIH for support of research activities. We made a payment of $0.6 million for the three months ended March 31, 2021. The CRADA expires in May 2023. In February 2018, we entered into an amendment to a CRADA with NIH that was originally executed between NIH and Amgen, Inc., or Amgen, in May 2012 and subsequently assigned by Amgen to the company effective as of December 17, 2015. The research goal of this CRADA, as amended, is for the non-clinical and clinical development of ganitumab, our licensed monoclonal antibody targeting insulin-like growth factor one receptor, to evaluate its safety and efficacy in patients with hematological malignancies and solid tumors. The CRADA has a five-year term commencing February 20, 2018 and expiring on February 20, 2023. During the term of the agreement, we are required to make minimum annual payments of $0.2 million to NIH for support of research activities and additional payments for the clinical trials based on the scope and phase of the clinical trials. Unpaid research and development expense was estimated at $0.4 million and $0.6 million as of March 31, 2021 and December 31, 2020, respectively. In February 2021, we entered into a CRADA with NIH to conduct collaborative analysis of human clinical trial samples from clinical trials utilizing our proprietary recombinant natural killer (NK) cells and/or monoclonal antibodies (mAbs) alone or in combination for the treatment of cancer and to pre-clinically study such agents. The CRADA has a two-year term commencing February 22, 2021 and expiring on February 22, 2023. During the term of the agreement, we are required to provide $0.1 million per year to NIH for support of research activities. We have $8,000 payable outstanding as of March 31, 2021 in connection with this CRADA agreement. All CRADA agreements may be terminated at any time upon the mutual written consent of the company and NIH. Either party may unilaterally terminate either of the CRADAs at any time by providing written notice to the other party at least 60 days before the desired termination date. Pursuant to the terms of the CRADAs, we have an option to elect to negotiate an exclusive or non-exclusive commercialization license to any inventions discovered in the performance of either of the CRADAs, whether solely by an NIH employee or jointly with a company employee for which a patent application has been filed. The parties jointly own any inventions and materials that are jointly produced by employees of both parties in the course of performing activities under the CRADAs. Royalties and In-licensing Agreements iosBio Ltd. Exclusive License Agreement In August 2020, we executed an exclusive license agreement with iosBio Ltd., formerly Stabilitech Biopharma Ltd. (“iosBio”), pursuant to which we and our affiliates will receive an exclusive, worldwide license to certain of iosBio’s intellectual property rights relating to the SARS-CoV-2 and successor vaccine candidates. In return, we are required to pay mid-to-high single-digit royalties on net sales of the resulting licensed products. Concurrently we entered into a non-exclusive license agreement with iosBio, which grants to iosBio and its affiliates a non-exclusive, worldwide license under the intellectual property and technology relating to our adenovirus constructs for the prevention and treatment of shingles and other infectious disease targets to be mutually agreed by the parties in good faith. As of March 31, 2021 and December 31, 2020, we accrued $0.1 million and $0.5 million payable, respectively, to iosBio for reimbursable costs related to the clinical trial activities initiated by iosBio.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Contingent Consideration Related to Business Combinations VivaBioCell, S.p.A. On April 10, 2015, NantWorks, a related party, acquired a 100% interest in VivaBioCell, S.p.A., or VivaBioCell, through its wholly-owned subsidiary, VBC Holdings, LLC, or VBC Holdings, for $0.7 million, less working capital adjustments. On June 15, 2015, NantWorks contributed its equity interest in VBC Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. In connection with this transaction, we are obligated to pay the former owners up to $3.7 million upon the achievement of certain sales milestones relating to scaffold technology and certain clinical and regulatory milestones relating to the GMP-in-a-Box technology. The fair value of the contingent consideration obligation decreased $0.1 million during the three months ended March 31, 2021 to $0.8 million. Altor BioScience Corporation In connection with our July 2017 acquisition of Altor BioScience Corporation, or Altor, we issued contingent value rights, or CVRs, under which we agreed to pay the prior stockholders of Altor approximately $304.0 million upon successful approval of the Biologics License Application, or BLA, or foreign equivalent, for Anktiva by December 31, 2022 and approximately $304.0 million upon the first calendar year before December 31, 2026 in which worldwide net sales of Anktiva exceed $1.0 billion (with amounts payable in cash or shares of our common stock or a combination thereof). Dr. Soon-Shiong and his related party hold approximately $279.5 million in the aggregate of CVRs and they have both irrevocably agreed to receive shares of the company’s common stock in satisfaction of their CVRs. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable. Contingencies We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. Altor BioScience, LLC Litigation The first action, Gray v. Soon-Shiong, et al. (Delaware Chancery Court, Case No. 2017-466-JRS), was filed on June 21, 2017, by plaintiffs Clayland Boyden Gray, or Gray, and Adam R. Waldman. The plaintiffs, two minority stockholders, asserted claims against the company and other defendants for (1) breach of fiduciary duty and (2) aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion on July 25, 2017, and permitted the merger to close. On September 1, 2017, plaintiffs (joined by two additional minority stockholders, Barbara Sturm Waldman and Douglas E. Henderson, or Henderson) filed a second amended complaint, asserting claims for (1) appraisal; (2) quasi-appraisal; (3) breach of fiduciary duty; and (4) aiding and abetting breach of fiduciary duty. On September 18, 2017, defendants moved to dismiss the second amended complaint, raising grounds that included a “standstill” agreement under which defendants maintained that Gray and Adam R. Waldman and Barbara Strum Waldman, or the Waldman’s, agreed not to bring the lawsuit. In the second action, Dyad Pharmaceutical Corp. v. Altor BioScience, LLC (Delaware Chancery Court, Case No. 2017-848-JRS), commenced November 28, 2017, Dyad Pharmaceutical Corporation, or Dyad, filed a petition for appraisal in connection with the merger. Respondent moved to dismiss the appraisal petition on January 26, 2018, arguing in part that the petition was barred by the same “standstill” agreement. On April 23, 2018, the court heard oral arguments on the motions to dismiss in both consolidated cases, and on June 26, 2018, the court converted the motions to dismiss into motions for summary judgment with regard to the “standstill” agreement argument, or the Converted Motions. The court permitted discovery into the meaning and intended scope of the “standstill” agreements, which the parties completed on December 19, 2018. The parties completed a briefing on the Converted Motions on March 15, 2019. The court heard an oral argument on the Converted Motions on May 7, 2019, and issued an oral ruling on May 15, 2019. The court (1) dismissed all claims brought by Gray and the Waldman’s except for their appraisal claims; (2) dismissed all plaintiffs’ quasi-appraisal claims; (3) dismissed the disclosure-based breach of fiduciary duty claims; and (4) dismissed Altor BioScience from the action. The following claims remain: (a) the appraisal claims by all plaintiffs and Dyad (against Altor BioScience, LLC), and (b) Henderson’s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty. On June 14, 2019, the defendants answered the second amended complaint, and the respondent answered Dyad’s appraisal petition. In their answer, defendants asserted counterclaims against Gray and the Waldman’s for breach of the “standstill” agreements and are seeking as damages the attorneys’ fees and costs they were forced to expend as a result of the breach. On June 20, 2019, the court issued a written order implementing its ruling on the Converted Motions, or the Implementing Order. In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o C. Boyden Gray, were dismissed. On July 11, 2019, Gray and the Waldman’s filed answers denying the counterclaims and asserting defenses. On September 30, 2019, plaintiffs moved for leave to file a third amended complaint. The proposed amendment sought to add two former Altor stockholders as plaintiffs and to add a fiduciary duty claim on behalf of a purported class of former Altor stockholders. On October 25, 2019, the defendants opposed the motion, and a briefing was completed on February 28, 2020. The court heard an oral argument on March 12, 2020, and granted the motion. The plaintiffs filed the third amended complaint on June 8, 2020. On June 29, 2020, defendants answered the third amended complaint and asserted counter claims against the plaintiffs. As damages, defendants seek the attorneys’ fees and costs incurred as a result of these breaches. On July 14, 2020, the plaintiffs filed an answer denying the counterclaims and asserting defenses. The trial has been set to commence in October 2021. The shares of these former Altor stockholders met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date. However, these dissenting shares will automatically be converted to receive the portion of the merger consideration they were entitled to, on the later of the closing date, and when the stockholder withdraws or loses the right to demand appraisal rights. Payment for dissenting shares will be on the same terms and conditions originally stated in the merger agreement. As of March 31, 2021 and December 31, 2020, we had accrued $6.9 million and $6.8 million related to these obligations, respectively. The accrued amount represents the estimated low-end of the range of currently estimated payout amounts in accordance with ASC Topic 450, Contingencies Sorrento Therapeutics, Inc. Litigation Sorrento Therapeutics, Inc. v. NantCell, Inc., et al. Sorrento Therapeutics, Inc., or Sorrento, derivatively on behalf of NANTibody, LLC, or NANTibody, filed an action in the Superior Court of California, Los Angeles County, or the Superior Court, against the company, Dr. Soon-Shiong and Charles Kim. The action alleges that the defendants improperly caused NANTibody to acquire IgDraSol, Inc. from our affiliate NantPharma, LLC, or NantPharma, and seeks to have the transaction undone, and seeks to have the purchase amount returned to NANTibody. Sorrento filed a related arbitration proceeding, or the Cynviloq arbitration, against Dr. Soon-Shiong and NantPharma; the company is not named in the Cynviloq arbitration. On May 15, 2019, we filed a demurrer to several causes of action alleged in the Superior Court action. On July 18, 2019, Sorrento filed an amended complaint, eliminating Charles Kim as a defendant and dropping the causes of action we had challenged in its demurrer. On May 24, 2019, we and Dr. Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. We and Dr. Soon-Shiong allege that Dr. Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento’s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. On October 9, 2019, the Superior Court ruled that our claims should be pursued in arbitration and that Dr. Soon-Shiong’s claims could be pursued in Superior Court. On February 13, 2020, after a full briefing, the Superior Court heard oral argument and granted Dr. Soon-Shiong’s request for a preliminary injunction barring Sorrento from pursuing claims against him in the Cynviloq arbitration. Sorrento then filed the claims it had previously asserted in arbitration against Dr. Soon-Shiong in the Superior Court on March 3, 2020, and at Sorrento’s request, the arbitrator entered an order dismissing Sorrento’s claims against Dr. Soon-Shiong in the Cynviloq arbitration on March 6, 2020. The hearing in the Cynviloq arbitration has been scheduled to commence in June 2021. On October 24, 2019, we, along with NANTibody, filed an arbitration against Sorrento and Dr. Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration on May 4, 2020, and requested leave to file a dispositive motion on May 1, 2020. On January 29, 2020, Sorrento sent letters purporting to terminate the exclusive license agreement with the company, and an exclusive license agreement with NANTibody and demanding the return of its confidential information and transfer of all regulatory filings and related materials. As required pursuant to the exclusive license agreements, both parties must engage in good-faith negotiations before attempting to invoke any termination provision contained in the agreement. Notwithstanding such negotiations, Sorrento sent a letter on April 10, 2020, purporting to terminate the exclusive license agreements, maintaining the negotiations did not reach a successful resolution. We believe we have cured any perceived breaches during the 90-day contractual cure period provided under the agreements. We intend to prosecute our claims, and to defend the claims asserted against us, vigorously. An estimate of the possible loss or range of loss cannot be made at this time. The hearings in the antibody arbitration commenced in April 2021 and are anticipated to be concluded in late July or early August 2021. Shenzhen Beike Biotechnology Corporation Litigation In July 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Shenzhen Beike Biotechnology Corporation, or Beike. The arbitration relates to a license, development, and commercialization agreement that Altor (succeeded by our wholly-owned subsidiary Altor BioScience, LLC, or Altor) entered into with Beike in September 2014, which agreement was amended and restated in September 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on Anktiva in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to Anktiva. Beike is seeking specific performance, or in the alternative, damages for the alleged breaches. On September 25, 2020, the parties entered into a standstill and tolling agreement under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement may be terminated by any party on ten calendar days’ notice, and upon termination, the parties will have the right to pursue claims arising from the license agreement in any appropriate tribunal. The parties have been asked to provide an update to the International Chamber of Commerce by May 31, 2021 of any further developments. Given that this action remains at the pleading stage and no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims lack merit and intend to defend the case vigorously and that we may have counterclaims. Fox Chase Litigation On July 21, 2020, ImmunityBio filed a declaratory judgment lawsuit in the Superior Court for San Diego County, California, naming Fox Chase Cancer Center Foundation and Institute for Cancer Research as the defendants (hereafter collectively “Fox Chase”). This litigation relates to the license with Fox Chase and includes various intellectual property rights (the “2004 License”). Our initial court filing requested that the Court find that we have not breached any material obligation under the 2004 License and that Fox Chase has not and cannot terminate the 2004 License. Fox Chase filed a Cross-Complaint raising a patent inventorship challenge and moved the case to federal court. See Part II, Item 1A., “ Risk Factors Litigation Related to the Merger with ImmunityBio, Inc. In connection with the Merger with NantCell, Inc. (formerly known as ImmunityBio, Inc., a private company), a Delaware corporation, via a wholly-owned subsidiary of NantKwest (the “Merger Sub”), Hargett v. NantKwest, Inc., et al. Franchi v. NantKwest, Inc., et al. Gross v. NantKwest, Inc., et al. Leaman v. NantKwest, Inc., et al. Weiss v. NantKwest, Inc., et al. Carlisle v. NantKwest, Inc., et al. Shenk v. NantKwest, Inc., et al. Lease Arrangements Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. We have leases in multiple facilities across the U.S. and Italy, including El Segundo, California (general corporate and administrative activities, research and development and regulatory from related parties); San Diego, California (research facility and office space); Culver City, California (research and manufacturing space from a related party); Torrance, California (a research facility from a related party); Miramar, Florida (clinical development); Seattle, Washington (research and development); Louisville, Colorado (research and development and manufacturing); Woburn, Massachusetts (research facility); and Udine and Tavangnacco, Italy (GMP-in-a-Box, research facility and office space). See Note 9 , Related Party Agreements Our leases generally have initial terms ranging from two to ten years one to five years Information regarding our leases is as follows: March 31, 2021 December 31, 2020 (Unaudited) Weighted average remaining lease term 4.6 years 3.9 years Weighted average discount rate 9 % 9 % The components of lease expense consist of the following (in thousands): Three Months Ended March 31, 2021 2020 (Unaudited) Operating lease costs $ 2,147 $ 1,782 Variable lease costs 666 848 Total lease costs $ 2,813 $ 2,630 Cash paid for amounts included in the measurement of lease liabilities is as follows (in thousands): Three Months Ended March 31, 2021 2020 (Unaudited) Operating cash flows for operating leases $ 1,679 $ 1,355 Future minimum lease payments as of March 31, 2021, including $4.9 million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in thousands). Common area maintenance costs and taxes are not included in these payments. Years ending December 31: Operating Leases 2021 (excluding the three months ended March 31, 2021) $ 5,193 2022 6,889 2023 5,135 2024 3,622 2025 3,183 Thereafter 2,487 Total future minimum lease payments 26,509 Less: Interest 4,799 Present value of operating lease liabilities $ 21,710 In February 2021, but effective on January 1, 2021, we entered into a lease agreement with 605 Nash, LLC, a related party, whereby we leased approximately 6,883 square feet in El Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease runs from January 2021 through December 2027, and includes an option to extend the lease for an additional three-year term through December 2030. Base rent for the term of the lease is approximately $20,300 per month with an annual increase of 3% on January 1 of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. See Note 9 , Related Party Agreements There have been no other material changes related to our existing lease agreements from those disclosed in Note 8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) filed as Exhibit 99.2 to our Current Report on Form 8‑K/A filed with the Securities and Exchange Commission, or SEC, on April 22, 2021. Commitments We did not enter into any significant contracts during the three months ended March 31, 2021, other than those disclosed in these condensed combined consolidated financial statements. In addition, we are also a party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There have been no material changes in unconditional purchase commitments from those disclosed in Note 8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) filed as Exhibit 99.2 to our Current Report on Form 8‑K/A filed with the Securities and Exchange Commission, or SEC, on April 22, 2021.

Related Party Agreements

Related Party Agreements	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Agreements	9. Related Party Agreements We conduct business with several affiliates under written agreements and informal arrangements. Below is a summary of outstanding balances and a description of significant relationships (in thousands): March 31, 2021 December 31, 2020 (Unaudited) Due from related party – NantBio $ 1,294 $ 1,294 Due from related party – NantOmics 591 591 Due from related parties – Various 172 118 Total due from related parties $ 2,057 $ 2,003 Due to related party – NantWorks $ 12,799 $ 10,650 Due to related party – Duley Road 3,161 2,787 Due to related party – NantBio 943 943 Due to related party – Immuno-Oncology Clinic 503 271 Due to related party – Nant Capital 224 — Due to related party – NantPharma 187 187 Total due to related parties $ 17,817 $ 14,838 Related-party notes payable – Nant Capital $ 150,695 $ 109,246 Related-party notes payable – NantMobile 57,078 56,660 Related-party notes payable – NantWorks 52,165 51,546 Related-party notes payable – NCSC 37,348 36,901 Total related-party notes payable $ 297,286 $ 254,353 Our Executive Chairman, and principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new genetically modified NK cells for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman. NantWorks Under the NantWorks shared services agreement executed in November 2015, but effective August 2015, NantWorks provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services. We are charged for the services at cost plus reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the employees providing the services. During the three months ended March 31, 2021 and 2020, we recorded $1.8 million and $1.5 million, respectively, in selling, general and administrative expense research and development expense As of March 31, 2021 and December 31, 2020, we owed NantWorks a net amount of $ 12.8 million and $ 10.7 million, respectively, for all agreements between the two affiliates, which is included in due to related parties on the condensed combined consolidated balance sheets . We also recorded $ 1.3 million and $ 1.1 million of prepaid expenses for services that have been passed through to the company from NantWorks as of March 31, 2021 and December 31, 2020, respectively, which are included in prepaid expenses and other current assets on the condensed combined consolidated balance sheets . In November 2015, we entered into a facility license agreement with NantWorks LLC, or NantWorks, a related party, for approximately 9,500 square feet of office space in Culver City, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The initial license was effective from May 2015 through December 2020. Base monthly rent for the initial lease term was $47,000, with annual increases of 3% beginning in January 2017. In September 2020, we amended this agreement to extend the term of this lease through December 31, 2021. Commencing January 1, 2021, the monthly rent increased by 3% to $54,500. Subsequent to December 31, 2021, the lease term will automatically renew on a month-to-month basis, terminable by either party with at least 30 days’ prior written notice to the other party. In addition, we have a one-time option to extend the lease term through December 31, 2022. If we exercise the option to extend the lease through December 31, 2022, or continue on a month-to-month basis, the monthly rent will increase by 3% annually commencing on January 1 of each year. On the date of amendment, we recognized an increase of $1.2 million in both operating lease right-of-use assets operating lease liabilities research and development expense Immuno-Oncology Clinic, Inc. Beginning in 2017, we entered into multiple agreements with Immuno-Oncology Clinic, Inc., or the Clinic (dba Chan Soon-Shiong Institutes for Medicine, in El Segundo, California), to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by one officer of the company and NantWorks manages the administrative operations of the Clinic. Prior to June 30, 2019, one of our officers was an investigator or sub-investigator for all of our trials conducted at the Clinic. In July 2019, we entered into a new agreement with the Clinic (the Clinic Agreement), which became effective on July 1, 2019. The Clinic Agreement, as amended on March 31, 2020, covers clinical trial and research-related activities on a non-exclusive basis relating to our existing clinical trials, commenced prior to July 1, 2019, and prospective clinical trials and research projects. The Clinic Agreement also specifies certain services and related costs that are excluded from the Clinic Agreement. Prior to commencing any work under the Clinic Agreement, the parties have agreed to execute written work orders setting forth the terms and conditions related to specific services to be performed, including financial terms. For clinical trials that commenced prior to July 1, 2019, fees incurred for services performed after July 1, 2019 are covered under the Clinic Agreement and applied towards the below-mentioned prepayments. The Clinic Agreement allows for automatic renewal and additional extensions beyond the initial one-year In consideration of the services to be performed under the Clinic Agreement, as amended on March 31, 2020, we agreed to make payments of up to $7.5 million to the Clinic, of which $3.75 million and $1.88 million were paid in July 2019 and October 2019, respectively. As amended, a conditional payment of $1.88 million shall be due and payable at such time, if any, that the payments made in July 2019 and October 2019 have been earned by the Clinic through the performance of services. On a quarterly basis, our prepayment is increased by an interest credit computed in accordance with terms specified in the Clinic Agreement. To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the Clinic Agreement, we may elect at our sole discretion either to (i) not extend the term of the Clinic Agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii) extend the term of the Clinic Agreement for up to three additional one year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60 days of expiration. The Clinic may terminate this agreement upon each anniversary date upon sixty (60) days prior written notice and reimbursement in full to us of any outstanding unearned balance of the prepayments, provided that any such termination by the Clinic will not apply with respect to any work orders still in effect at the time of such termination. In July 2019, we executed a clinical trial work order under the Clinic Agreement for an open-label, Phase I study of PD‑L1.t‑haNK for infusion in subjects with locally advanced or metastatic solid cancers. In July 2020, but effective on June 22, 2020, we and NantCell, Inc. (formerly known as ImmunityBio, Inc., a private company) executed a clinical trial work order under our existing master agreement with the Clinic for an open-label, randomized, comparative Phase II study of NantCell’s proprietary IL‑15 superagonist (N‑803) and Aldoxorubicin Hydrochloride (Aldoxorubicin) and our PD‑L1.t‑haNK with standard-of-care chemotherapy versus standard-of-care chemotherapy for first and second-line treatment of locally or advanced metastatic pancreatic cancer. During the three months ended March 31, 2021 and 2020, $0.3 million and $0.1 million, respectively, was recognized in research and development expense NantBio, Inc. In March 2016, NantBio and the National Cancer Institute, or the NCI, entered into a cooperative research and development agreement. The initial five-year prepaid expenses and other current assets In August 2018, we entered into a supply agreement with NantCancerStemCell, LLC, or NCSC, a 60% owned subsidiary of NantBio (with the other 40% owned by Sorrento). Under this agreement, we agreed to supply VivaBioCell’s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement has an initial term of five years one-year due to related parties In 2018, we entered into a shared service agreement, pursuant to which, we are charged for services at cost, without mark-up or profit for NantBio, but including reasonable allocations of employee benefits that relate to the employees providing the services. In April 2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects, comprising the majority of NantBio’s business, to the company. After the transfer, NantBio continued to make payments on our behalf for certain employee benefits and vendor costs related to the research and development projects that were transferred to the company. In addition, we settled certain employee bonuses and benefits that were accrued by NantBio for 2018. As of March 31, 2021 and December 31, 2020, we recorded a net receivable from NantBio of $1.3 million, which included $1.0 million for employee bonuses and $0.3 million for vendor costs we paid on behalf of NantBio. NantOmics In June 2019, we made a strategic decision and transferred certain employees from NantOmics, LLC, or NantOmics, a related party that is controlled by our Executive Chairman, to the company. After the transfer, we settled certain employee bonuses and benefits that were accrued by NantOmics for the year ended December 31, 2020 and recorded a $0.6 million receivable from NantOmics as of March 31, 2021 and December 31, 2020. 605 Doug St, LLC In September 2016, we entered into a lease agreement with 605 Doug St, LLC, an entity owned by our Executive Chairman, for approximately 24,250 square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July 2016 through July 2023. We have the option to extend the lease for an additional three-year research and development expense Duley Road, LLC In February 2017, Altor BioScience Corporation (succeeded by our wholly-owned subsidiary Altor BioScience, LLC), or Altor, through its wholly-owned subsidiary, entered into a lease agreement with Duley Road, LLC, or Duley Road, a related party, that is indirectly controlled by our Executive Chairman, for approximately 12,000 square feet of office and cGMP manufacturing facility space in El Segundo, California. The lease term is from February 2017 through October 2024. We have the option to extend the initial term for two consecutive five-year research and development expense Effective in January 2019, we entered into two lease agreements with Duley Road for a second building located in El Segundo, California. The first lease is for the first floor of the building with approximately 5,650 square feet. The lease has a seven-year seven-year five-year As of March 31, 2021 and December 31, 2020, we recorded $0.9 million and $0.7 million of leasehold improvement payables, respectively, and $0.8 million and $1.1 million of lease-related payables to Duley Road, which were included in due to related parties research and development expense other assets 605 Nash, LLC In February 2021, but effective on January 1, 2021, we entered into a lease agreement with 605 Nash, LLC, a related party, whereby we leased approximately 6,883 square feet in El Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease runs from January 2021 through December 2027, and includes an option to extend the lease for an additional three-year We are responsible for the build out of the facility space and have incurred costs of approximately $7.0 million as of March 31, 2021, which is reflected as construction in progress within property, plant and equipment, net , on the condensed combined consolidated balance sheets. We are also entitled to a tenant improvement allowance of $0.3 million associated with the buildout costs, which is recorded in prepaid expenses and other current assets on the condensed combined consolidated balance sheets. For the three months ended March 31, 2021, we recorded rent expense of $0.1 million, which is reflected in research and development expense on the condensed combined consolidated statements of operations. NantPharma In 2018, Altor BioScience, LLC and GlobeImmune, Inc. purchased a total of $0.2 million in laboratory equipment from NantPharma. As of March 31, 2021 and December 31, 2020, we recorded a $0.2 million payable to NantPharma. Related Party Notes Payable In December 2015, we executed a demand promissory note with Nant Capital. The note bears interest at a per annum rate of 5.0%, compounded annually and computed on the basis of 365 or 366 days. In July 2020 and August 2020, we borrowed $10.0 million and $3.7 million from Nant Capital, respectively. In July 2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September 30, 2025, and not on demand. The principal amount of advances made by the related party pursuant to these notes totaled $55.2 million, all of which was outstanding as of March 31, 2021 and December 31, 2020, respectively. Accrued and unpaid interest on this note totaled $4.0 million and $3.3 million as of March 31, 2021 and December 31, 2020, respectively. Amounts due under this promissory note are included in related-party notes payable In June 2017, we executed a demand promissory note with NantWorks. The note bears interest at a per annum rate of 5.0 %, compounded annually and computed on the basis of 365 or 366 days. In July 2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September 30, 2025, and not on demand. We may prepay the outstanding principal amount at any time without premium or penalty and the prior consent of NantWorks. All outstanding amounts under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount of advances made by the related party pursuant to these notes totaled $ 43.4 million , all of which was outstanding as of March 31, 2021 and December 31, 2020, respectively. Accrued and unpaid interest on this note totaled $ million and $ 8.1 million as of March 31, 2021 and December 31, 2020, respectively. Amounts due under this promissory note are included in related-party notes payable , on the condensed combined consolidated balance sheets. In August 2018, we executed a demand promissory note with NCSC. The note bears interest at a per annum rate of 5.0%, compounded annually and computed on the basis of 365 or 366 days. In July 2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September 30, 2025, and not on demand. All amounts outstanding under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount of advances made by the related party pursuant to these notes totaled $33.0 million, all of which was outstanding as of March 31, 2021 and December 31, 2020, respectively. Accrued and unpaid interest on this note amounted to $4.3 million and $3.9 million as of March 31, 2021 and December 31, 2020, respectively. Amounts due under this promissory note are included in related-party notes payable In December 2019, we executed a demand promissory note with NantMobile. The note bears interest at a per annum rate of 3.0%, compounded annually and computed on the basis of 365 or 366 days. In July 2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September 30, 2025, and not on demand. We may prepay the outstanding principal amount at any time without premium or penalty and the prior consent of NantMobile. All amounts outstanding under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount advanced by the related party pursuant to this note was $55.0 million, all of which was outstanding as of March 31, 2021 and December 31, 2020, respectively. Accrued and unpaid interest on this note amounted to $2.1 million and $1.7 million as of March 31, 2021 and December 31, 2020, respectively. Amounts due under this promissory note are included in related-party notes payable In September 2020, we executed a promissory note with Nant Capital for an advance of the principal of $50.0 million, all of which was outstanding as of March 31, 2021 and December 31, 2020. The note bears interest at a per annum rate of 6.0%, compounded annually and computed on the basis of 365 or 366 days. The outstanding principal and accrued and unpaid interest are due and payable on September 30, 2025. Accrued and unpaid interest on this note amounted to $1.5 million and $0.8 million as of March 31, 2021 and December 31, 2020, respectively. Amounts due under this promissory note are included in related-party notes payable In February 2021, we executed a promissory note with Nant Capital. The outstanding principal amount of each advance made by Nant Capital bears interest at a per annum rate of 6.0%, compounded annually and computed based on 365 or 366 days. On February 26, 2021, we received a $40.0 million advance pursuant to this promissory note, all of which is outstanding as of March 31, 2021. The accrued interest shall be paid quarterly commencing on June 30, 2021. The outstanding principal amount and any accrued and unpaid interest are due on September 30, 2025. We may prepay the outstanding principal amount and accrued interest at any time without premium or penalty and the prior consent of Nant Capital. Accrued interest payable on this note amounted to $0.2 million as of March 31, 2021, and was included in due to related parties related-party notes payable All demand promissory notes have no equity or equity-linked convertible rights.

Stockholders_ Deficit

Stockholders’ Deficit	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders’ Deficit	10. Stockholders’ Deficit Merger with NantCell Under the terms of the Merger Agreement, at the Effective Time of the Merger, each share of NantCell common stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive 0.8190 newly issued shares of common stock At the Effective Time, each share of our common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. Since the Merger has been accounted for as a transaction between entities under common control, the outstanding shares presented on the condensed combined consolidated financial statements assume that NantCell outstanding common stock was converted into shares of Company Common Stock for all periods presented, and in connection with the conversion, those shares of common stock have been recorded at the company’s par value of $0.0001 per share. Stock Repurchases In November 2015, the board of directors approved a share repurchase program, or the 2015 Share Repurchase Program, allowing the Chief Executive officer, or CEO, or Chief Financial Officer, or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0 million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. Shares repurchased under this program are formally retired through board approval upon repurchase. No shares were repurchased during the three months ended March 31, 2021 and 2020. As of March 31, 2021, $18.3 million remained authorized for repurchase under the 2015 Share Repurchase Program. Common Stock Reserved for Future Issuance As of March 31, 2021, a total of approximately 12.6 million shares of common stock were reserved for issuance, including awards issued under the NC 2015 Plan that were outstanding immediately prior to the Effective Time of the Merger.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation 2015 Equity Incentive Plan In July 2015, the company’s board of directors adopted, and the company’s stockholders approved the 2015 Plan. As of March 31, 2021, the 2015 Plan is the only equity plan of the company available for grant of equity awards to employees, directors and consultants of the company. As of March 31, 2021, a total of approximately 6.2 million shares were available for future grant under the 2015 Plan. Stock-based Compensation The following table presents stock-based compensation included on the condensed combined consolidated statements of operations (in thousands): Three Months Ended March 31, 2021 2020 (Unaudited) Stock-based compensation expense: Stock options $ 6,355 $ 130 RSUs 8,943 350 $ 15,298 $ 480 Stock-based compensation expense in operating expenses: Research and development $ 2,888 $ 161 Selling, general and administrative 12,410 319 $ 15,298 $ 480 On March 18, 2021, the Board of Directors approved to modify certain non-qualified stock options that were assumed in the Merger and otherwise would have expired during a period when the grantees were legally restricted from exercising these awards. The expiration date of these options was extended to thirty (30) days following our registration statement effective date. We recognized incremental stock-based compensation expense of approximately $2.7 million for this stock option modification. On March 29, 2021, in connection with the resignation of two former directors, the Board of Directors approved the acceleration of vesting of 83,333 shares of unvested stock options of each of the former directors on the date of their respective resignations. The modified options are exercisable for ninety (90) days after the date of the modification. We recognized incremental stock-based compensation expense of approximately $2.3 million for this stock option modification. The stock option modifications were measured as the excess of the fair value of the modified awards over the fair value of the original awards immediately before the modifications. The incremental stock-based compensation was recognized in selling, general and administrative expenses Stock Options The following table summarizes stock option activity and related information for three months ended March 31, 2021: Number of Shares Weighted- Average Exercise Price Aggregate Intrinsic Value (in thousands) Weighted- Average Remaining Contractual Life (in years) Outstanding at December 31, 2020 4,996,284 $ 9.96 $ 29,746 4.7 Options granted 750,000 $ 23.72 Options exercised (752,310 ) $ 2.39 Options forfeited (15,660 ) $ 6.27 Outstanding at March 31, 2021 4,978,314 $ 13.21 $ 54,279 5.4 Vested and exercisable at March 31, 2021 3,815,630 $ 12.07 $ 46,363 4.2 On the the c c e o fficer, a stock option award “ the (i.e., date of date of grant Mr. c s 2015 Mr. c e o fficer c ompany, effective Mr. Adcock’s offer As of March 31, 2021, the unrecognized compensation cost related to outstanding stock options was $13.9 million, which is expected to be recognized over a remaining weighted-average period of 2.8 years. The total intrinsic value of stock options exercised during the three months ended March 31, 2021 was $11.1 million. Cash proceeds received from stock option exercises during the three months ended March 31, 2021 was $1.1 million. There were no stock options exercised during the three months ended March 31, 2020. As of December 31, 2020, a total of 4,345,497 vested and exercisable shares were outstanding. The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions: Three Months Ended March 31, 2021 (Unaudited) Expected term (in years) 6.0 Risk-free interest rate 0.6 % Expected volatility 100.5 % Dividend yield 0.0 % Weighted-average grant date fair value $ 18.63 The expected term was estimated using the average of the contractual term and the weighted-average vesting term of the options. The risk-free interest rate was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected volatility was estimated based on the historical volatility of our common stock. The assumed dividend yield was based on our expectation of not paying dividends in the foreseeable future. There were no stock options granted during the three months ended March 31, 2020. Restricted Stock Units The following table summarizes RSU activity for the three months ended March 31, 2021: Number of Shares Weighted- Average Grant Date Fair Value Unvested balance at December 31, 2020 466,842 $ 2.52 Granted 7,521,110 $ 25.35 Vested (235,725 ) $ 16.34 Forfeited/canceled (116,095 ) $ 25.49 Unvested balance at March 31, 2021 7,636,132 $ 24.23 As of March 31, 2021, there was $179.2 million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 3.9 years. We may grant RSUs to both employees and directors of the company and to employees of related parties that provide shared services to the company under our shared services agreement with NantWorks as discussed in Note 9 , Related Party Agreements On the the c Award” collectively, Awards”) 2015 Awards Aw a rd date of grant c c ompany’s Aw a rd Aw a rd date of grant date of g Mr. c s 2015 Mr. c e o fficer c ompany, effective Mr. Adcock’s offer On March 4, 2021, prior to the Merger, NantCell awarded 7,121,110 RSUs (adjusted for the exchange ratio of 0.8190) to employees and consultants of NantCell and its affiliated companies, pursuant to the NC 2015 Plan. These RSU awards were subject to a performance condition in connection with a “Liquidity Event”, defined as either (i) NantCell’s registration of shares for issuance on a securities offering or (ii) the closing of a corporate transaction. In addition, the vesting of certain performance-based RSU grants accelerates upon obtaining approval by the FDA of a BLA or equivalent application for approval of Anktiva for use in the treatment of non-muscle-invasive bladder cancer. These performance-based RSUs are also subject to service conditions and are scheduled to cliff vest on the last date of each tranche as defined by the individual grant agreements. On March 9, 2021, we completed the Merger with NantCell, and the performance condition related to the Liquidity Event was met. The fair value of the RSUs was estimated based on a third-party valuation as of the grant date of March 4, 2021 and was derived primarily from the estimated probabilities of the Merger close on March 9, 2021 and the other exit assumptions. Once the liquidity event related performance condition was met as of March 9, 2021 due to the Merger, compensation expense for these RSUs began to be recognized on a graded vesting attribution approach over the requisite service period for each participant, which ranges from six-month research and development expense selling, general and administrative expense The RSUs awarded to employees and consultants of affiliated companies were accounted for as stock-based compensation in accordance with ASU 2018-07, Compensation—Stock Compensation (Topic 718) Note 9 , Related Party Agreements additional paid in capital, Warrants In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell’s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of 1,638,000 warrants with an exercise price of $3.24 per share, with vesting subject to the achievement of a certain performance condition pertaining to building manufacturing capacity, were outstanding as of March 31, 2021. The fair value of $18.0 million assigned to the unvested warrants will be recognized upon achievement of a performance-based vesting condition pertaining to building manufacturing capacity to support supply requirements for one of our product candidates

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes On March 9, 2021, the company completed the Merger with NantCell. The merger is accounted for as a transaction between entities under common control. The Merger is also considered a nontaxable transaction for U.S. income tax purposes and it is intended to qualify as a “reorganization” within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended. The company is subject to taxation in the United States, various state, and foreign jurisdictions. Earnings from non-U.S. activities are subject to local country income tax. The company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. No tax benefit was provided for losses incurred in the United States, Italy, and South Korea because those losses are offset by a full valuation allowance. The difference between the federal statutory tax rate of 21 % and the company’s 0 % tax rate is due to losses from which the company cannot benefit. The company is no longer subject to income tax examination by the U.S. federal, state or local tax authorities for years ended December 31, 2015 or prior; however, its tax attributes, such as net operating loss (“NOL”) carryforwards and tax credits, are still subject to examination in the year they are used.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events Immuno-Oncology Clinic, Inc. Agreement During April 2021, ImmunityBio executed two work orders under an existing master agreement with Immuno-Oncology Clinic, Inc. (the “Clinic”), a related party. Under these work orders, the parties agreed that the Clinic would serve as a site for the following multi-site clinical trials: • A Phase I study of the safety, reactogenicity, and immunogenicity of subcutaneously- and orally-administered supplemental spike & nucleocapsid-targeted COVID ‑ 19 vaccine to enhance T cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use; and • A Phase I study of the safety, reactogenicity, and immunogenicity of a supplemental spike & nucleocapsid-targeted COVID ‑ 19 vaccine to enhance T cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use. Pursuant to our existing agreement with the Clinic, our share of qualifying expenses shall be deducted from amounts previously paid to the Clinic as described in further detail in Note 9 , Related Party Agreements . We expect to incur up to $0.2 million of qualifying clinical trial expenses under each work order, subject to changes dependent on clinical trial enrollments and progress. Open Market Sale Agreement On April 30, 2021, we entered into an Open Market Sale Agreement (the “Sale Agreement”) with respect to an at-the-market (“ATM”) offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $500.0 million through our sales agent. We will pay our sales agent a commission of up to 3.0% of the gross sales proceeds of any shares of our common stock sold through them under the Sale Agreement, and also have provided them with customary indemnification and contribution rights. We are not obligated to sell any shares under the Sale Agreement and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all of the shares.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Accounting Treatment of the Merger	Accounting Treatment of the Merger The Merger represents a business combination pursuant to Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 805-50, Mergers
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed combined consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, and pursuant to the rules and regulations of the SEC. The unaudited condensed combined consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed combined consolidated financial statements do not include all information and notes required by U.S. GAAP for annual reports. As of March 31, 2021, the company had an accumulated deficit of $1.7 billion. We also had negative cash flows from operations of $60.5 million for the three months ended March 31, 2021. The company will likely need additional capital to further fund the development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products. The condensed combined consolidated financial statements are derived from the company’s and NantCell’s respective historical consolidated financial statements for each period presented. Since the entities have been under common control for all periods presented, the condensed combined consolidated financial statements assume that the Merger took place at the beginning of the earliest period for which the condensed combined consolidated financial statements are presented. Accordingly, these financial statements should be read in conjunction with the audited combined consolidated financial statements and notes thereto for the fiscal year ended December 31, 2020 included in the Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) filed as Exhibit 99.2 to our Current Report on Form 8‑K/A filed with the SEC on April 22, 2021. Interim operating results are not necessarily indicative of operating results for the full year. The condensed combined consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $500.0 million of our common stock that may be issued and sold under an “at-the-market” sales agreement with Jefferies LLC, or the ATM, and our potential ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12 months following the issuance date of the financial statements based primarily upon our Executive Chairman’s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed combined consolidated financial statements include the accounts of the company and its subsidiaries. All intercompany amounts have been eliminated. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest in our condensed combined consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. We apply the variable interest model under ASC Topic 810, Consolidation For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model. Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20% to 50% interest in the voting securities of the entity. All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in interest and investment income, net Fair Value Measurement Investments—Equity Securities Prior to March 31, 2021, we owned non-marketable equity securities that were accounted for using the measurement alternative under ASC 321 because the preferred stock held by us was not considered in-substance common stock and such preferred stock did not have a readily determinable fair value. All investments are reviewed for possible impairment on a regular basis. If an investment’s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include: the investees’ earnings performance and clinical trial performance, change in the investees’ industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee’s ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include: the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.
Use of Estimates	Use of Estimates The preparation of condensed combined consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed combined consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.
Risks and Uncertainties	Risks and Uncertainties In March 2020, the World Health Organization declared the novel strain of coronavirus disease (SARS‑CoV‑2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.
Contingencies	Contingencies We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable. Our cash and cash equivalents are held by one major financial institution in the U.S., one in South Korea and one in Italy. Product candidates developed by us will require approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation
Basic and Diluted Net Loss Per Share of Common Stock	Basic and Diluted Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of p otentially dilutive securities: As of March 31, 2021 2020 (Unaudited) Outstanding stock options 4,978,314 6,080,483 Outstanding RSUs 7,636,132 1,102,528 Outstanding related-party warrants 1,638,000 1,638,000 Total 14,252,446 8,821,011 Amounts in the table above reflect the common stock equivalents of the noted instruments, including awards issued under the NantKwest 2015 Equity Incentive Plan (the “2015 Plan”), the NantKwest 2014 Equity Incentive Plan (the “2014 Plan”), and awards issued under the NantCell, Inc. 2015 Stock Incentive Plan (the “NC 2015 Plan”) that, in the case of March 31, 2021, were outstanding immediately prior to the Effective Time of the Merger and in the case of March 31, 2020 have been adjusted to include the combined NC 2015 Plan and NantCell warrants then outstanding (in both cases adjusted using the Merger Exchange Ratio of 0.8190 Note 11 , Stock-Based Compensation
Recent Accounting Pronouncements	Recent Accounting Pronouncements Application of New or Revised Accounting Standards – Not Yet Adopted In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016‑13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three months ended March 31, 2021 did not, or are not expected to, have a material effect on our consolidated financial statements.
Fair Value Measurements	Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: • Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of bank deposits, money market funds, and marketable equity securities. • Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level 2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities. • Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement. We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.

Description of Business (Tables

Description of Business (Tables)	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations	The following table provides the impact of the change in reporting entity on our unaudited condensed combined consolidated statements of operations for the three months ended March 31, 2021 and 2020 (in thousands): Three Months Ended March 31, 2021 NantCell NantKwest Intercompany Eliminations ImmunityBio, Inc. Revenue $ 183 $ — $ (44 ) $ 139 Operating expenses: Research and development (including amounts with related parties) 21,509 19,725 (106 ) 41,128 Selling, general and administrative (including amounts with related parties) 24,382 20,903 (10 ) 45,275 Loss from operations (45,708 ) (40,628 ) 72 (86,264 ) Other (expense) income, net (including amounts with related parties) (848 ) 6,637 — 5,789 Income tax expense — (6 ) — (6 ) Net loss $ (46,556 ) $ (33,997 ) $ 72 $ (80,481 ) Three Months Ended March 31, 2020 NantCell NantKwest Intercompany Eliminations ImmunityBio, Inc. Revenue $ 168 $ 21 $ (24 ) $ 165 Operating expenses: Research and development (including amounts with related parties) 14,252 13,234 (112 ) 27,374 Selling, general and administrative (including amounts with related parties) 4,120 5,373 — 9,493 Loss from operations (18,204 ) (18,586 ) 88 (36,702 ) Other (expense) income, net (including amounts with related parties) (910 ) 203 — (707 ) Income tax expense (18 ) — — (18 ) Net loss $ (19,132 ) $ (18,383 ) $ 88 $ (37,427 )

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Securities Excluded from the Computation of Potentially Dilutive Securities	The following table details those securities that have been excluded from the computation of p otentially dilutive securities: As of March 31, 2021 2020 (Unaudited) Outstanding stock options 4,978,314 6,080,483 Outstanding RSUs 7,636,132 1,102,528 Outstanding related-party warrants 1,638,000 1,638,000 Total 14,252,446 8,821,011

Financial Statement Details (Ta

Financial Statement Details (Tables)	3 Months Ended
	Mar. 31, 2021
Financial Statement Details [Abstract]
Prepaid Expenses and Other Current Assets	As of March 31, 2021 and December 31, 2020, prepaid expenses and other current assets consist of the following (in thousands): March 31, 2021 December 31, 2020 (Unaudited) Prepaid preclinical and clinical trial services – with related party (Note 9) $ 4,648 $ 4,626 Insurance claim receivable 2,932 2,518 Prepaid services 1,435 1,294 Prepaid license fees 1,329 801 Prepaid insurance 1,230 1,365 Insurance premium financing asset 571 1,421 Prepaid rent 569 589 Equipment deposits 375 66 Tenant improvement receivables – with related party (Note 9) 313 — Prepaid equipment maintenance 239 243 Interest receivable – 132 473 Prepaid supplies – with related party (Note 9) 131 143 Other 338 110 Prepaid expenses and other current assets $ 14,242 $ 13,649
Property, Plant and Equipment, Net	As of March 31, 2021 and December 31, 2020, property, plant and equipment, net, consist of the following (in thousands): March 31, 2021 December 31, 2020 (Unaudited) Leasehold improvements $ 52,200 $ 52,251 Equipment 38,556 34,738 Buildings 22,690 22,690 Construction in progress 8,308 1,333 Software 2,659 2,376 Furniture & fixtures 1,007 1,015 Gross property, plant and equipment 125,420 114,403 Less: Accumulated depreciation and amortization 44,545 41,862 Property, plant and equipment, net $ 80,875 $ 72,541
Other Assets	As of March 31, 2021 and December 31, 2020, other assets consist of the following (in thousands): March 31, 2021 December 31, 2020 (Unaudited) VAT receivable $ 810 $ 864 Security deposits 319 634 Prepaid software license fees 227 455 Restricted cash 179 179 Due from related party 54 51 Prepaid preclinical and clinical trial services – with related party (Note 9) — 92 Other 316 323 Other assets $ 1,905 $ 2,598
Accrued Expenses and Other Liabilities	As of March 31, 2021 and December 31, 2020, accrued expenses and other liabilities consist of the following (in thousands): March 31, 2021 December 31, 2020 (Unaudited) Accrued bonus $ 6,947 $ 5,288 Accrued dissenting shares (Note 8) 6,854 6,769 Accrued professional and service fees 6,728 7,668 Accrued preclinical and clinical trial costs 4,656 4,339 Accrued compensation 4,349 3,891 Accrued research and development costs 2,103 4,002 Accrued construction costs 1,931 — Accrued contingent consideration payable 822 856 Accrued laboratory equipment and supplies 681 641 Financing obligation – 571 1,421 Deferred revenue 263 270 Accrued franchise, sales, use and property taxes 113 103 Accrued capital expenditures 16 337 Other 759 1,186 Accrued expenses and other liabilities $ 36,793 $ 36,771
Interest and Investment Income, Net	Interest and investment income, net consists of the following (in thousands): Three Months Ended March 31, 2021 2020 (Unaudited) Unrealized gains (losses) from equity securities $ 8,833 $ (198 ) Interest income 339 322 Investment amortization expense, net (225 ) (45 ) Net realized losses on investments (3 ) (1 ) Interest and investment income, net $ 8,944 $ 78

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2021
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-Sale Marketable Debt Securities	As of March 31, 2021, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in thousands): March 31, 2021 (Unaudited) Weighted- Average Remaining Contractual Life (in years) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Current: Corporate debt securities 0.2 $ 15,541 $ 1 $ (4 ) $ 15,538 Mutual funds 35 2 — 37 Current portion 15,576 3 (4 ) 15,575 Noncurrent: Foreign bonds 5.1 861 139 — 1,000 Noncurrent portion 861 139 — 1,000 Total $ 16,437 $ 142 $ (4 ) $ 16,575 As of December 31, 2020, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in thousands): December 31, Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Current: Corporate debt securities $ 54,789 $ 2 $ (19 ) $ 54,772 Mutual funds 35 2 — 37 Current portion 54,824 4 (19 ) 54,809 Noncurrent: Foreign bonds 861 89 — 950 Noncurrent portion 861 89 — 950 Total $ 55,685 $ 93 $ (19 ) $ 55,759
Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position	Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12 months and for more than 12 months as of March 31, 2021 and December 31, 2020 were as follows (in thousands): March 31, 2021 (Unaudited) Less than 12 months More than 12 months Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Corporate debt securities $ 13,535 $ (4 ) $ — $ — Total $ 13,535 $ (4 ) $ — $ — December 31, 2020 Less than 12 months More than 12 months Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Corporate debt securities $ 42,762 $ (19 ) $ — $ — Total $ 42,762 $ (19 ) $ — $ —

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March 31, 2021 and December 31, 2020 (in thousands): Fair Value Measurements as of March 31, 2021 (Unaudited) Total Level 1 Level 2 Level 3 Assets: Current: Cash and cash equivalents $ 44,679 $ 44,679 $ — $ — Equity securities (1) 23,019 23,019 — — Corporate debt securities 15,538 — 15,538 — Mutual funds 37 37 — — Noncurrent: Foreign bonds 1,000 1,000 — — Total assets measured at fair value $ 84,273 $ 68,735 $ 15,538 $ — Liabilities: Contingent consideration obligations (2) $ (844 ) $ — $ — $ (844 ) Fair Value Measurements as of December 31, 2020 Total Level 1 Level 2 Level 3 Assets: Current: Cash and cash equivalents $ 34,915 $ 34,915 $ — $ — Corporate debt securities 54,772 — 54,772 — Equity securities 6,337 6,337 — — Mutual funds 37 37 — — Noncurrent: Foreign bonds 950 950 — — Total assets measured at fair value $ 97,011 $ 42,239 $ 54,772 $ — Liabilities: Contingent consideration obligations (2) $ (972 ) $ — $ — $ (972 ) (1) Our equity securities include our investment in Viracta totaling $14.5 million, which was previously accounted for by applying the measurement alternative under ASC 321. In February 2021, Viracta merged with Sunesis Pharmaceuticals, Inc., a public company. In connection with this transaction, our preferred stock investment in Viracta was converted into 1,562,604 shares of Viracta common stock effective February 25, 2021. See Note 4 , Equity Investment in Viracta Therapeutics , for additional information. (2) Contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level 3 measurement within the fair value hierarchy) and are reviewed periodically by management. See Note 8 , Commitments and Contingencies, for additional information.
Summary of Changes in Carrying Amount of Contingent Consideration Obligations	Changes in the carrying amount of contingent consideration obligations were as follows (in thousands): Three Months Ended March 31, 2021 2020 (Unaudited) Fair value, beginning of period $ (972 ) $ (1,725 ) Net change in fair value 128 (2 ) Fair value, end of period $ (844 ) $ (1,727 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Lessee Disclosure [Abstract]
Summary of Information Regarding Leases	Information regarding our leases is as follows: March 31, 2021 December 31, 2020 (Unaudited) Weighted average remaining lease term 4.6 years 3.9 years Weighted average discount rate 9 % 9 % The components of lease expense consist of the following (in thousands): Three Months Ended March 31, 2021 2020 (Unaudited) Operating lease costs $ 2,147 $ 1,782 Variable lease costs 666 848 Total lease costs $ 2,813 $ 2,630 Cash paid for amounts included in the measurement of lease liabilities is as follows (in thousands): Three Months Ended March 31, 2021 2020 (Unaudited) Operating cash flows for operating leases $ 1,679 $ 1,355
Summary of Future Minimum Lease Payments	Future minimum lease payments as of March 31, 2021, including $4.9 million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in thousands). Common area maintenance costs and taxes are not included in these payments. Years ending December 31: Operating Leases 2021 (excluding the three months ended March 31, 2021) $ 5,193 2022 6,889 2023 5,135 2024 3,622 2025 3,183 Thereafter 2,487 Total future minimum lease payments 26,509 Less: Interest 4,799 Present value of operating lease liabilities $ 21,710

Related Party Agreements (Table

Related Party Agreements (Tables)	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Summary of Outstanding Balances of Related Party Agreements	Below is a summary of outstanding balances and a description of significant relationships (in thousands): March 31, 2021 December 31, 2020 (Unaudited) Due from related party – NantBio $ 1,294 $ 1,294 Due from related party – NantOmics 591 591 Due from related parties – Various 172 118 Total due from related parties $ 2,057 $ 2,003 Due to related party – NantWorks $ 12,799 $ 10,650 Due to related party – Duley Road 3,161 2,787 Due to related party – NantBio 943 943 Due to related party – Immuno-Oncology Clinic 503 271 Due to related party – Nant Capital 224 — Due to related party – NantPharma 187 187 Total due to related parties $ 17,817 $ 14,838 Related-party notes payable – Nant Capital $ 150,695 $ 109,246 Related-party notes payable – NantMobile 57,078 56,660 Related-party notes payable – NantWorks 52,165 51,546 Related-party notes payable – NCSC 37,348 36,901 Total related-party notes payable $ 297,286 $ 254,353

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation Expenses Included on Operations Statement	The following table presents stock-based compensation included on the condensed combined consolidated statements of operations (in thousands): Three Months Ended March 31, 2021 2020 (Unaudited) Stock-based compensation expense: Stock options $ 6,355 $ 130 RSUs 8,943 350 $ 15,298 $ 480 Stock-based compensation expense in operating expenses: Research and development $ 2,888 $ 161 Selling, general and administrative 12,410 319 $ 15,298 $ 480
Summarizes Stock Option Activity and Related Information Under Equity Incentive Plans	The following table summarizes stock option activity and related information for three months ended March 31, 2021: Number of Shares Weighted- Average Exercise Price Aggregate Intrinsic Value (in thousands) Weighted- Average Remaining Contractual Life (in years) Outstanding at December 31, 2020 4,996,284 $ 9.96 $ 29,746 4.7 Options granted 750,000 $ 23.72 Options exercised (752,310 ) $ 2.39 Options forfeited (15,660 ) $ 6.27 Outstanding at March 31, 2021 4,978,314 $ 13.21 $ 54,279 5.4 Vested and exercisable at March 31, 2021 3,815,630 $ 12.07 $ 46,363 4.2
Weighted Average of Fair Value of Options Under Black-Scholes Option-Pricing Model	The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions: Three Months Ended March 31, 2021 (Unaudited) Expected term (in years) 6.0 Risk-free interest rate 0.6 % Expected volatility 100.5 % Dividend yield 0.0 % Weighted-average grant date fair value $ 18.63
RSUs Activity	The following table summarizes RSU activity for the three months ended March 31, 2021: Number of Shares Weighted- Average Grant Date Fair Value Unvested balance at December 31, 2020 466,842 $ 2.52 Granted 7,521,110 $ 25.35 Vested (235,725 ) $ 16.34 Forfeited/canceled (116,095 ) $ 25.49 Unvested balance at March 31, 2021 7,636,132 $ 24.23

Description of Business - Addit

Description of Business - Additional Information (Detail) $ / shares in Units, $ in Millions	Mar. 09, 2021$ / shares	Mar. 31, 2021USD ($)$ / shares	Mar. 31, 2021USD ($)$ / shares	Dec. 31, 2020$ / shares
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Merger exchange ratio	0.8190
Effective date of acquisition			Mar. 9, 2021
NantKwest
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Ownership percentage held by stockholders upon consummation of merger	28.50%
Executive Chairman and Principal Stockholder and Affiliates
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Ownership percentage held by Executive Chairman upon consummation of merger	81.80%
NantCell, Inc.
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Date of agreement and plan of merger			Dec. 21, 2020
Common stock, par value	$ 0.001
Ownership percentage held by stockholders upon consummation of merger	71.50%
Selling General and Administrative Expenses
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Merger related costs | $		$ 23.2	$ 12.9

Description of Business - Sched

Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Name Change Event [Line Items]
Revenue	$ 139	$ 165
Operating expenses:
Research and development (including amounts with related parties)	41,128	27,374
Selling, general and administrative (including amounts with related parties)	45,275	9,493
Loss from operations	(86,264)	(36,702)
Other (expense) income, net (including amounts with related parties)	5,789	(707)
Income tax expense	(6)	(18)
Net loss	(80,481)	(37,427)
Reportable Legal Entities | NantCell, Inc.
Name Change Event [Line Items]
Revenue	183	168
Operating expenses:
Research and development (including amounts with related parties)	21,509	14,252
Selling, general and administrative (including amounts with related parties)	24,382	4,120
Loss from operations	(45,708)	(18,204)
Other (expense) income, net (including amounts with related parties)	(848)	(910)
Income tax expense	0	(18)
Net loss	(46,556)	(19,132)
Reportable Legal Entities | NantKwest, Inc.
Name Change Event [Line Items]
Revenue	0	21
Operating expenses:
Research and development (including amounts with related parties)	19,725	13,234
Selling, general and administrative (including amounts with related parties)	20,903	5,373
Loss from operations	(40,628)	(18,586)
Other (expense) income, net (including amounts with related parties)	6,637	203
Income tax expense	(6)	0
Net loss	(33,997)	(18,383)
Intercompany Eliminations
Name Change Event [Line Items]
Revenue	(44)	(24)
Operating expenses:
Research and development (including amounts with related parties)	(106)	(112)
Selling, general and administrative (including amounts with related parties)	(10)	0
Loss from operations	72	88
Other (expense) income, net (including amounts with related parties)	0	0
Income tax expense	0	0
Net loss	$ 72	$ 88

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	Apr. 30, 2021USD ($)	Mar. 09, 2021	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)
Accounting Policies [Line Items]
Accumulated deficit			$ 1,694,745,000		$ 1,615,131,000
Net cash used in operating activities			$ 60,469,000	$ 31,107,000
Merger exchange ratio		0.8190
NC 2015 Plan and NantCell Warrants
Accounting Policies [Line Items]
Merger exchange ratio		0.8190
Maximum | VIE
Accounting Policies [Line Items]
Percentage of ownership interest			50.00%
Minimum | VIE
Accounting Policies [Line Items]
Percentage of ownership interest			20.00%
ATM Offering Program | Subsequent Events | Maximum
Accounting Policies [Line Items]
Maximum aggregate offering price	$ 500,000,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	14,252,446	8,821,011
Outstanding Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	4,978,314	6,080,483
Outstanding RSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	7,636,132	1,102,528
Outstanding Related Party Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,638,000	1,638,000

Financial Statement Details - P

Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Prepaid preclinical and clinical trial services – with related party (Note 9)	$ 4,648	$ 4,626
Insurance claim receivable	2,932	2,518
Prepaid services	1,435	1,294
Prepaid license fees	1,329	801
Prepaid insurance	1,230	1,365
Insurance premium financing asset	571	1,421
Prepaid rent	569	589
Equipment deposits	375	66
Tenant improvement receivables – with related party (Note 9)	313	0
Prepaid equipment maintenance	239	243
Interest receivable – marketable debt securities	132	473
Prepaid supplies – with related party (Note 9)	131	143
Other	338	110
Prepaid expenses and other current assets	$ 14,242	$ 13,649

Financial Statement Details -_2

Financial Statement Details - Property, Plant and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 125,420	$ 114,403
Less: Accumulated depreciation and amortization	44,545	41,862
Property, plant and equipment, net	80,875	72,541
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	52,200	52,251
Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	38,556	34,738
Buildings
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	22,690	22,690
Construction in Progress
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	8,308	1,333
Software
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	2,659	2,376
Furniture And Fixtures
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,007	$ 1,015

Financial Statement Details - A

Financial Statement Details - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Financial Statement Details [Abstract]
Depreciation and amortization	$ 2,972	$ 3,461

Financial Statement Details - O

Financial Statement Details - Other Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Other Assets Noncurrent [Abstract]
VAT receivable	$ 810	$ 864
Security deposits	319	634
Prepaid software license fees	227	455
Restricted cash	179	179
Due from related party	54	51
Prepaid preclinical and clinical trial services – with related party (Note 9)	0	92
Other	316	323
Other assets	$ 1,905	$ 2,598

Financial Statement Details -_3

Financial Statement Details - Accrued Expenses and Other Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accrued Liabilities Current [Abstract]
Accrued bonus	$ 6,947	$ 5,288
Accrued dissenting shares (Note 8)	6,854	6,769
Accrued professional and service fees	6,728	7,668
Accrued preclinical and clinical trial costs	4,656	4,339
Accrued compensation	4,349	3,891
Accrued research and development costs	2,103	4,002
Accrued construction costs	1,931	0
Accrued contingent consideration payable	822	856
Accrued laboratory equipment and supplies	681	641
Financing obligation – current portion	571	1,421
Deferred revenue	263	270
Accrued franchise, sales, use and property taxes	113	103
Accrued capital expenditures	16	337
Other	759	1,186
Accrued expenses and other liabilities	$ 36,793	$ 36,771

Financial Statement Details - I

Financial Statement Details - Interest and Investment Income, Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Investment Income Net [Abstract]
Unrealized gains (losses) from equity securities	$ 8,833	$ (198)
Interest income	339	322
Investment amortization expense, net	(225)	(45)
Net realized losses on investments	(3)	(1)
Interest and investment income, net	$ 8,944	$ 78

Equity Investment in Viracta _2

Equity Investment in Viracta Therapeutics - Additional Information (Detail) - USD ($) $ in Thousands	Feb. 25, 2021	Jan. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	May 31, 2019	Mar. 31, 2017
Schedule Of Investments [Line Items]
Non-marketable equity investment (Note 4)					$ 0		$ 7,849		$ 8,500
Unrealized gains on marketable securities					14	$ 23
Interest and Investment Income, Net
Schedule Of Investments [Line Items]
Unrealized loss on equity investment							$ 1,400
Viracta Therapeutics, Inc.
Schedule Of Investments [Line Items]
Unrealized gains on marketable securities					6,600
Marketable securities					$ 14,500
Viracta Therapeutics, Inc. | Common Stock | Sunesis Pharmaceuticals, Inc
Schedule Of Investments [Line Items]
Preferred stock investment converted into common stock, shares	1,562,604
2018 Note and Warrant Purchase Agreement | Viracta Therapeutics, Inc.
Schedule Of Investments [Line Items]
Purchase of convertible note			$ 400	$ 400
2018 Note and Warrant Purchase Agreement | Series B Preferred Stock | Viracta Therapeutics, Inc.
Schedule Of Investments [Line Items]
Unrealized gains on marketable securities		$ 800
2018 Note and Warrant Purchase Agreement | Common Stock | Viracta Therapeutics, Inc.
Schedule Of Investments [Line Items]
Warrants exercised to acquire shares								253,120

Financial Instruments - Summary

Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale, Amortized Cost	$ 16,437	$ 55,685
Available-for-sale, Gross Unrealized Gains	142	93
Available-for-sale, Gross Unrealized Losses	(4)	(19)
Available-for-sale, Fair Value	16,575	55,759
Current Assets
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale, Amortized Cost	15,576	54,824
Available-for-sale, Gross Unrealized Gains	3	4
Available-for-sale, Gross Unrealized Losses	(4)	(19)
Available-for-sale, Fair Value	15,575	54,809
Current Assets | Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale, Amortized Cost	15,541	54,789
Available-for-sale, Gross Unrealized Gains	1	2
Available-for-sale, Gross Unrealized Losses	(4)	(19)
Available-for-sale, Fair Value	$ 15,538	54,772
Available-for-sale, Weighted- Average Remaining Contractual Life	2 months 12 days
Current Assets | Mutual Funds
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale, Amortized Cost	$ 35	35
Available-for-sale, Gross Unrealized Gains	2	2
Available-for-sale, Gross Unrealized Losses	0	0
Available-for-sale, Fair Value	37	37
Noncurrent Assets
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale, Amortized Cost	861	861
Available-for-sale, Gross Unrealized Gains	139	89
Available-for-sale, Gross Unrealized Losses	0	0
Available-for-sale, Fair Value	1,000	950
Noncurrent Assets | Foreign Bonds
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale, Amortized Cost	861	861
Available-for-sale, Gross Unrealized Gains	139	89
Available-for-sale, Gross Unrealized Losses	0	0
Available-for-sale, Fair Value	$ 1,000	$ 950
Available-for-sale, Weighted- Average Remaining Contractual Life	5 years 1 month 6 days

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021USD ($)Security	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)
Schedule Of Available For Sale Securities [Line Items]
Unrealized gains (losses) from equity securities	$ 8,834,000	$ (202,000)
Equity Securities
Schedule Of Available For Sale Securities [Line Items]
Investments in marketable equity securities with readily determinable fair values	23,000,000		$ 6,300,000
Unrealized gains (losses) from equity securities	8,800,000	(200,000)
Realized gains or losses on sales of equity securities	$ 0	$ 0
Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Number of available-for-sale securities in unrealized loss positions | Security	14
Other than temporary impairment losses	$ 0

Financial Instruments - Accumul

Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Available-for-Sale Investments, Less than 12 months, Estimated Fair Value	$ 13,535	$ 42,762
Available-for-Sale Investments, Less than 12 months, Gross Unrealized Losses	(4)	(19)
Available-for-Sale Investments, More than 12 months, Estimated Fair Value	0	0
Available-for-Sale Investments, More than 12 months, Gross Unrealized Losses	0	0
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Available-for-Sale Investments, Less than 12 months, Estimated Fair Value	13,535	42,762
Available-for-Sale Investments, Less than 12 months, Gross Unrealized Losses	(4)	(19)
Available-for-Sale Investments, More than 12 months, Estimated Fair Value	0	0
Available-for-Sale Investments, More than 12 months, Gross Unrealized Losses	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 84,273	$ 97,011
Contingent consideration obligations	(844)	(972)
Current Assets | Cash and Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	44,679	34,915
Current Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	15,538	54,772
Current Assets | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	23,019	6,337
Current Assets | Mutual Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	37	37
Noncurrent Assets | Foreign Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	1,000	950
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	68,735	42,239
Contingent consideration obligations	0	0
Level 1 | Current Assets | Cash and Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	44,679	34,915
Level 1 | Current Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	0	0
Level 1 | Current Assets | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	23,019	6,337
Level 1 | Current Assets | Mutual Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	37	37
Level 1 | Noncurrent Assets | Foreign Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	1,000	950
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	15,538	54,772
Contingent consideration obligations	0	0
Level 2 | Current Assets | Cash and Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	0	0
Level 2 | Current Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	15,538	54,772
Level 2 | Current Assets | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	0	0
Level 2 | Current Assets | Mutual Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	0	0
Level 2 | Noncurrent Assets | Foreign Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	0	0
Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	0	0
Contingent consideration obligations	(844)	(972)
Level 3 | Current Assets | Cash and Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	0	0
Level 3 | Current Assets | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	0	0
Level 3 | Current Assets | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	0	0
Level 3 | Current Assets | Mutual Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	0	0
Level 3 | Noncurrent Assets | Foreign Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail) - Viracta Therapeutics, Inc. - USD ($) $ in Millions	Feb. 25, 2021	Mar. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities		$ 14.5
Common Stock | Sunesis Pharmaceuticals, Inc
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Preferred stock investment converted into common stock, shares	1,562,604

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Changes in Carrying Amount of Contingent Consideration Obligations (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value, beginning of period	$ (972)	$ (1,725)
Net change in fair value	128	(2)
Fair value, end of period	$ (844)	$ (1,727)

Collaboration and License Agr_2

Collaboration and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Feb. 28, 2021	Jan. 31, 2018	Mar. 31, 2021	Dec. 31, 2020
National Institutes of Health | CRADA
Licensing Agreement [Line Items]
Annual payment for support of research activities	$ 100,000
Minimum annual payments for support of research activities		$ 200,000
Estimated unpaid research and development expense			$ 400,000	$ 600,000
Payable outstanding			8,000
National Institutes of Health | CRADA | Etubics Corporation
Licensing Agreement [Line Items]
Annual payment for support of research activities		$ 600,000	600,000
Clinical Trial Activities | iosBio Ltd. Exclusive License Agreement
Licensing Agreement [Line Items]
Accrued reimbursable costs payable			$ 100,000	$ 500,000

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	Jun. 15, 2015	Apr. 10, 2015	Mar. 31, 2021	Dec. 31, 2020
Lessee Lease Description [Line Items]
Operating lease payments related to options to extend lease terms			$ 4.9
Minimum
Lessee Lease Description [Line Items]
Initial term of lease arrangement			2 years
Optional extended lease term			1 year
Maximum
Lessee Lease Description [Line Items]
Initial term of lease arrangement			10 years
Optional extended lease term			5 years
Altor BioScience Corporation
Lessee Lease Description [Line Items]
Minimum net sales milestone for contingent value rights payable			$ 1,000
Altor BioScience Corporation | Dr. Soon-Shiong and Related Party
Lessee Lease Description [Line Items]
Contingent value rights payable			279.5
Altor BioScience Corporation | Contingent Value Rights Payable if Certain Conditions are met by December 31, 2022
Lessee Lease Description [Line Items]
Contingent value rights payable			304
Altor BioScience Corporation | Contingent Value Rights Payable if Certain Conditions are met on or before December 31, 2026
Lessee Lease Description [Line Items]
Contingent value rights payable			304
Altor BioScience, LLC
Lessee Lease Description [Line Items]
Accrual for dissenting shares			6.9	$ 6.8
VivaBioCell
Lessee Lease Description [Line Items]
Ownership percentage acquired		100.00%
Business combination, consideration transferred		$ 0.7
Maximum milestone payment due if certain conditions are met	$ 3.7
Change in fair value of contingent consideration obligation			0.1
Fair value of contingent consideration obligation			$ 0.8

Commitment and Contingencies _2

Commitment and Contingencies - Summary of Information Regarding Leases (Detail)	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted average remaining lease term	4 years 7 months 6 days	3 years 10 months 24 days
Weighted average discount rate	9.00%	9.00%

Commitment and Contingencies _3

Commitment and Contingencies - Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Lease Cost [Abstract]
Operating lease costs	$ 2,147	$ 1,782
Variable lease costs	666	848
Total lease costs	$ 2,813	$ 2,630

Commitment and Contingencies _4

Commitment and Contingencies - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash Flow Operating Activities Lessee [Abstract]
Operating cash flows for operating leases	$ 1,679	$ 1,355

Commitment and Contingencies _5

Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail) $ in Thousands	Mar. 31, 2021USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2021 (excluding the three months ended March 31, 2021)	$ 5,193
2022	6,889
2023	5,135
2024	3,622
2025	3,183
Thereafter	2,487
Total future minimum lease payments	26,509
Less: Interest	4,799
Present value of operating lease liabilities	$ 21,710

Related Party Agreements - Summ

Related Party Agreements - Summary of Outstanding Balances of Related Party Agreements (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Total due from related parties	$ 2,057	$ 2,003
Total due to related parties	17,817	14,838
Total related-party notes payable	297,286	254,353
NantBio
Related Party Transaction [Line Items]
Total due from related parties	1,294	1,294
Total due to related parties	943	943
NantOmics
Related Party Transaction [Line Items]
Total due from related parties	591	591
Various
Related Party Transaction [Line Items]
Total due from related parties	172	118
NantWorks
Related Party Transaction [Line Items]
Total due to related parties	12,799	10,650
Total related-party notes payable	52,165	51,546
Duley Road
Related Party Transaction [Line Items]
Total due to related parties	3,161	2,787
Immuno-Oncology Clinic
Related Party Transaction [Line Items]
Total due to related parties	503	271
NantPharma
Related Party Transaction [Line Items]
Total due to related parties	187	187
Nant Capital
Related Party Transaction [Line Items]
Total due to related parties	224	0
Total related-party notes payable	150,695	109,246
NantMobile
Related Party Transaction [Line Items]
Total related-party notes payable	57,078	56,660
NCSC
Related Party Transaction [Line Items]
Total related-party notes payable	$ 37,348	$ 36,901

Related Party Agreements - Addi

Related Party Agreements - Additional Information (Detail)

Feb. 26, 2021USD ($)

Jan. 01, 2021USD ($)

Feb. 28, 2021USD ($)ft²

Sep. 30, 2020USD ($)

Oct. 31, 2019USD ($)

Jul. 31, 2019USD ($)

Aug. 31, 2018

Feb. 28, 2017USD ($)ft²Term

Nov. 30, 2015USD ($)ft²Officer

Mar. 31, 2021USD ($)ft²

Mar. 31, 2020USD ($)

Dec. 31, 2018USD ($)

Dec. 31, 2020USD ($)

Aug. 31, 2020USD ($)

Jul. 31, 2020USD ($)

Dec. 31, 2019

Jun. 30, 2017

Dec. 31, 2015

Related Party Transaction [Line Items]

Selling, general and administrative expense

$ 45,275,000

$ 9,493,000

Research and development

41,128,000

27,374,000

Due to related parties

17,817,000

$ 14,838,000

Right-of-use assets obtained in exchange for operating lease liabilities

1,388,000

0

Deferred revenue

263,000

270,000

Security deposits

319,000

634,000

Related-party notes payable

297,286,000

254,353,000

NantBioScience

Related Party Transaction [Line Items]

Net receivable

$ 1,300,000

1,300,000

Nant Cancer Stem Cell L L C | Sorrento

Related Party Transaction [Line Items]

Percentage of ownership interest by parent

40.00%

Nant Cancer Stem Cell L L C | NantBioScience

Related Party Transaction [Line Items]

Percentage of ownership interest by parent

60.00%

Maximum

Related Party Transaction [Line Items]

Initial term of lease arrangement

10 years

Optional extended lease term

5 years

Minimum

Related Party Transaction [Line Items]

Initial term of lease arrangement

2 years

Optional extended lease term

1 year

NantWorks

Related Party Transaction [Line Items]

Number of square foot of facility leased | ft²

9,500

Base rent - monthly

$ 47,000

Percentage of annual increases of base rent

3.00%

Lease agreement extended lease period

Dec. 31, 2021

NantWorks | Research and Development

Related Party Transaction [Line Items]

Lease expense

$ 200,000

100,000

NantWorks | Amendment to Extend Lease Term

Related Party Transaction [Line Items]

Base rent - monthly

$ 54,500

Right-of-use assets obtained in exchange for operating lease liabilities

$ 1,200,000

NantWorks | Shared Services Agreement

Related Party Transaction [Line Items]

Selling, general and administrative expense

1,800,000

1,500,000

Research and development

300,000

1,000,000

Prepaid expenses

1,300,000

1,100,000

NantWorks | Shared Services Agreement | Reimbursements

Related Party Transaction [Line Items]

Due to related parties

12,800,000

10,700,000

Immuno-Oncology Clinic, Inc. | California

Related Party Transaction [Line Items]

Research and development

300,000

100,000

Due to related parties

$ 500,000

300,000

Number of officers | Officer

1

Initial term of agreement

1 year

Related party transaction installment payment

$ 1,880,000

$ 3,750,000

Related party transaction conditional payment

1,880,000

Notice period to terminate new agreement

60 days

Prepaid balance related to Clinic Agreement

$ 4,600,000

4,700,000

Immuno-Oncology Clinic, Inc. | California | Maximum

Related Party Transaction [Line Items]

Estimated cost for new agreement with clinic

$ 7,500,000

NantBioScience

Related Party Transaction [Line Items]

Research and development

$ 100,000

100,000

Initial term of agreement entered into with the related party by the entity

5 years

Research and development expense, ratable payment period

12 months

Prepayment for services amount

$ 600,000

NantBioScience | Prepaid Expenses and Other Current Assets

Related Party Transaction [Line Items]

Prepaid balance included in prepaid expenses and other current assets and other assets

0

100,000

Nant Cancer Stem Cell L L C

Related Party Transaction [Line Items]

Initial term of agreement entered into with the related party by the entity

5 years

Related party, agreement renewal term

1 year

Revenue recognized

0

0

Nant Cancer Stem Cell L L C | Bioreactors

Related Party Transaction [Line Items]

Due to related parties

900,000

900,000

Deferred revenue

300,000

400,000

Employee Bonuses Payment | NantBioScience

Related Party Transaction [Line Items]

Net receivable

1,000,000

1,000,000

Employee Bonuses Payment | NantOmics

Related Party Transaction [Line Items]

Net receivable

600,000

600,000

Vendor Costs Payments | NantBioScience

Related Party Transaction [Line Items]

Net receivable

300,000

300,000

605 Doug St, LLC

Related Party Transaction [Line Items]

Base rent - monthly

$ 100,000

Percentage of annual increases of base rent

3.00%

Optional extended lease term

3 years

Due between the parties

$ 0

0

605 Doug St, LLC | El Segundo California

Related Party Transaction [Line Items]

Number of square foot of facility leased | ft²

24,250

605 Doug St, LLC | Research and Development

Related Party Transaction [Line Items]

Lease expense

$ 200,000

200,000

Duley Road, LLC

Related Party Transaction [Line Items]

Base rent - monthly

$ 40,700

Lease expense

100,000

100,000

Optional extended lease term

5 years

Annual percentage increases to monthly fixed charge

3.00%

Rent payable

$ 1,500,000

1,000,000

Options to extend number of terms | Term

2

Period of agreement

The lease term is from February 2017 through October 2024. We have the option to extend the initial term for two consecutive five-year periods through July 2034. The monthly rent is $40,700 with annual increases of 3% which began in November 2018.

Leasehold improvement payables

$ 900,000

700,000

Lease-related payables

800,000

1,100,000

Security deposits

100,000

100,000

Duley Road, LLC | El Segundo California

Related Party Transaction [Line Items]

Number of square foot of facility leased | ft²

12,000

Duley Road, LLC | Research and Development

Related Party Transaction [Line Items]

Lease expense

400,000

$ 100,000

Duley Road, LLC | 7-Year Term Commencing in September 2019

Related Party Transaction [Line Items]

Base rent - monthly

$ 35,800

Percentage of annual increases of base rent

3.00%

Optional extended lease term

5 years

Initial term of lease arrangement

7 years

Duley Road, LLC | 7-Year Term Commencing in September 2019 | El Segundo California

Related Party Transaction [Line Items]

Number of square foot of facility leased | ft²

5,650

Duley Road, LLC | Seven-Year Term Commencing in July 2019

Related Party Transaction [Line Items]

Base rent - monthly

$ 35,800

Percentage of annual increases of base rent

3.00%

Optional extended lease term

5 years

Initial term of lease arrangement

7 years

Duley Road, LLC | Seven-Year Term Commencing in July 2019 | El Segundo California

Related Party Transaction [Line Items]

Number of square foot of facility leased | ft²

6,488

605 Nash, LLC | El Segundo California

Related Party Transaction [Line Items]

Number of square foot of facility leased | ft²

6,883

Base rent - monthly

$ 20,300

Percentage of annual increases of base rent

3.00%

Optional extended lease term

3 years

605 Nash, LLC | Prepaid Expenses and Other Current Assets

Related Party Transaction [Line Items]

Tenant improvements allowance

$ 300,000

605 Nash, LLC | Property, Plant and Equipment, Net

Related Party Transaction [Line Items]

Construction in progress

7,000,000

605 Nash, LLC | Research and Development

Related Party Transaction [Line Items]

Lease expense

100,000

NantPharma

Related Party Transaction [Line Items]

Due to related parties

187,000

187,000

Laboratory equipment purchased

$ 200,000

Nant Capital

Related Party Transaction [Line Items]

Due to related parties

224,000

0

Nant Capital | Demand Promissory Note

Related Party Transaction [Line Items]

Note interest rate per annum

5.00%

Amount of note borrowed

$ 3,700,000

$ 10,000,000

Nant Capital | Promissory Note

Related Party Transaction [Line Items]

Note interest rate per annum

6.00%

6.00%

Amount of advance received

$ 40,000,000

Amount of advance received on note outstanding

40,000,000

Nant Capital | Related Party Notes Payable | Demand Promissory Note

Related Party Transaction [Line Items]

Related-party notes payable

55,200,000

55,200,000

Accrued and unpaid interest on note

4,000,000

3,300,000

Nant Capital | Related Party Notes Payable | Promissory Note

Related Party Transaction [Line Items]

Related-party notes payable

$ 50,000,000

50,000,000

50,000,000

Accrued and unpaid interest on note

1,500,000

800,000

Accrued interest payable

200,000

NantWorks

Related Party Transaction [Line Items]

Due to related parties

12,799,000

10,650,000

NantWorks | Demand Promissory Note

Related Party Transaction [Line Items]

Note interest rate per annum

5.00%

NantWorks | Related Party Notes Payable | Demand Promissory Note

Related Party Transaction [Line Items]

Related-party notes payable

43,400,000

43,400,000

Accrued and unpaid interest on note

8,800,000

8,100,000

NCSC | Demand Promissory Note

Related Party Transaction [Line Items]

Note interest rate per annum

5.00%

NCSC | Related Party Notes Payable | Demand Promissory Note

Related Party Transaction [Line Items]

Related-party notes payable

33,000,000

33,000,000

Accrued and unpaid interest on note

4,300,000

3,900,000

NantMobile | Demand Promissory Note

Related Party Transaction [Line Items]

Note interest rate per annum

3.00%

NantMobile | Related Party Notes Payable | Demand Promissory Note

Related Party Transaction [Line Items]

Related-party notes payable

55,000,000

55,000,000

Accrued and unpaid interest on note

$ 2,100,000

$ 1,700,000

Stockholders' Deficit - Additio

Stockholders' Deficit - Additional Information (Detail) $ / shares in Units, $ in Millions	Mar. 09, 2021$ / sharesshares	Mar. 04, 2021	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2020shares	Dec. 31, 2020$ / shares
Class Of Stock [Line Items]
Merger exchange ratio	0.8190
Common stock, par value | $ / shares	$ 0.0001		$ 0.0001		$ 0.0001
Shares issued	273,700,000
Total amount authorized for repurchase | $			$ 50
Remaining authorized repurchase amount | $			$ 18.3
Repurchase of common stock, shares			0	0
Total shares reserved for future issuance			12,600,000
NC 2015 Plan
Class Of Stock [Line Items]
Merger exchange ratio		0.8190
Total shares reserved for future issuance			0
NC 2015 Plan | RSUs
Class Of Stock [Line Items]
Total shares reserved for future issuance			7,000,000
NC 2015 Plan | Stock Options
Class Of Stock [Line Items]
Total shares reserved for future issuance			1,300,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Thousands	Mar. 29, 2021shares	Mar. 18, 2021USD ($)	Mar. 09, 2021shares	Mar. 04, 2021shares	Feb. 05, 2021Award$ / sharesshares	Mar. 31, 2021USD ($)Director$ / sharesshares	Mar. 31, 2020USD ($)shares	Dec. 31, 2020shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 15,298	$ 480
Option expiration date extended period						30 days
Number of board of directors | Director						2
Modified options exercisable period						90 days
Proceeds from stock options exercised						$ 1,121	0
Shares issued | shares			273,700,000
Merger exchange ratio			0.8190
Estimated benefit at grant date fair value						4,000
Deemed dividends						$ 100
Exercise price of warrants | $ / shares						$ 3.24
Fair value of warrants						$ 18,000
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						2,888	161
Selling General and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						12,410	$ 319
Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award options vested number of shares | shares	83,333
Unrecognized compensation cost related to unvested stock options						$ 13,900
Weighted-average period for recognition						2 years 9 months 18 days
Stock options, options granted | shares						750,000	0
Weighted average exercise price, options granted | $ / shares						$ 23.72
Share-based compensation arrangement by share-based payment award, award vesting rights						one-third of the Option Grant (i.e., 250,000 options) shall vest in equal installments on each of the first, second, and third anniversaries of the date of grant, such that all shares shall be fully vested on the third anniversary of the date of grant, subject to Mr. Adcock remaining in continuous service as defined in the 2015 Plan through the applicable vesting dates.
Proceeds from stock options exercised						$ 11,100
Aggregate intrinsic value of stock option exercised						$ 1,100
Exercise of stock options, Shares | shares						752,310	0
Stock Options, Vested and Exercisable | shares						3,815,630		4,345,497
Stock Options, Options granted | shares						750,000	0
Outstanding RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 8,943	$ 350
Share-based compensation arrangement by share-based payment award options vested number of shares | shares					83,333
Weighted-average period for recognition						3 years 10 months 24 days
Unrecognized compensation cost related to non-vested stock options						$ 179,200
Grants of restricted stock | shares						7,521,110
Outstanding RSUs | NantCell, Inc.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 5,100
Outstanding RSUs | NantCell, Inc. | Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						2,900
Outstanding RSUs | NantCell, Inc. | Selling General and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 2,200
Outstanding RSUs | NantCell, Inc. | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award requisite service period						6 months
Outstanding RSUs | NantCell, Inc. | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award requisite service period						70 months
Warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of warrants outstanding | shares						1,638,000
Modification of Stock Options Associated with Postponement of Termination Date
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 2,700
Non-employee Director | Modification of Stock Options Associated with Resignation
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 2,300
Two Thousand Fifteen Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future grants | shares						6,200,000
Number of awards granted | Award					2
Two Thousand Fifteen Equity Incentive Plan | Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options, options granted | shares					750,000
Weighted average exercise price, options granted | $ / shares					$ 23.72
Stock Options, Options granted | shares					750,000
Two Thousand Fifteen Equity Incentive Plan | Outstanding RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grants of restricted stock | shares					400,000
First RSU Award
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued | shares					150,000
Second RSU Award
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued | shares					250,000
NC 2015 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Merger exchange ratio				0.8190
NC 2015 Plan | NantCell, Inc.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grants of restricted stock | shares				7,121,110

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 15,298	$ 480
Stock Options
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	6,355	130
RSUs
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	8,943	350
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	2,888	161
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 12,410	$ 319

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock Option Activity (Detail) - Stock Option - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Number of Shares
Stock Options, Beginning Balance	4,996,284
Stock Options, Options granted	750,000	0
Stock Options, Options exercised	(752,310)	0
Stock Options,Options forfeited	(15,660)
Stock Options, Ending Balance	4,978,314		4,996,284
Stock Options, Vested and Exercisable	3,815,630		4,345,497
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning balance	$ 9.96
Weighted Average Exercise Price, Options granted	23.72
Weighted Average Exercise Price, Options exercised	2.39
Weighted Average Exercise Price, Options forfeited	6.27
Weighted Average Exercise Price, Outstanding Ending balance	13.21		$ 9.96
Weighted Average Exercise Price, Vested and Exercisable	$ 12.07
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding, Beginning balance	$ 29,746
Aggregate Intrinsic Value, Outstanding, Ending balance	54,279		$ 29,746
Aggregate Intrinsic Value, Vested and Exercisable	$ 46,363
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Outstanding	5 years 4 months 24 days		4 years 8 months 12 days
Weighted Average Remaining Contractual Life, Vested and Exercisable	4 years 2 months 12 days

Stock-Based Compensation - Blac

Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail) - Employee Stock Option - Stock Option	3 Months Ended
	Mar. 31, 2021$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years
Risk-free interest rate	0.60%
Expected volatility	100.50%
Dividend yield	0.00%
Weighted-average grant date fair value	$ 18.63

Stock-Based Compensation - RSUs

Stock-Based Compensation - RSUs Activity (Detail) - RSUs	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested, Beginning balance | shares	466,842
Number of Shares, Granted | shares	7,521,110
Number of Shares, Vested | shares	(235,725)
Number of Shares, Forfeited/canceled | shares	(116,095)
Number of Shares, Unvested, Ending balance | shares	7,636,132
Weighted-Average Grant Date Fair Value, Unvested, beginning balance | $ / shares	$ 2.52
Weighted-Average Grant Date Fair Value, Granted | $ / shares	25.35
Weighted-Average Grant Date Fair Value, Vested | $ / shares	16.34
Weighted-Average Grant Date Fair Value, Forfeited/canceled | $ / shares	25.49
Weighted-Average Grant Date Fair Value, Unvested, ending balance | $ / shares	$ 24.23

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax [Line Items]
Income tax expense (benefit)	$ 6,000	$ 18,000
Federal statutory tax rate	21.00%
Company's effective tax rate	0.00%
United States
Income Tax [Line Items]
Income tax expense (benefit)	$ 0
Italy
Income Tax [Line Items]
Income tax expense (benefit)	0
South Korea
Income Tax [Line Items]
Income tax expense (benefit)	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Events - Maximum	Apr. 30, 2021USD ($)
Immuno-Oncology Clinic, Inc. | Work Order 1
Subsequent Event [Line Items]
Expected clinical trial expense	$ 200,000
Immuno-Oncology Clinic, Inc. | Work Order 2
Subsequent Event [Line Items]
Expected clinical trial expense	200,000
ATM Offering Program
Subsequent Event [Line Items]
Maximum aggregate offering price	$ 500,000,000
Percentage of sales agent commission	3.00%